Conference abstracts
Abstracts
1733 abstracts. Filter by title, author, or session.
Novel targets and treatments for stimulant use disorders and depression
Social-neurobehavioral phenotypes for advancement of social-target intervention in cocaine use disorder
Feasibility and preliminary efficacy of tirzepatide for individuals with moderate/severe methamphetamine use disorder
Accelerated course of intermittent theta burst for methamphetamine use disorder: Feasibility and EEG-derived functional connectivity correlates of treatment response
Integrating cognitive-behavioral therapy with repetitive transcranial magnetic stimulation (CBT/TMS): A novel combined neuromodulation-psychotherapy model for prenatal depression
Conducting clinical trials using combined treatment modalities: Challenges, opportunities, and insights for future regulatory consideration
Cognitive behavioral therapy following esketamine for major depression and suicidal ideation for relapse prevention: The CBT-ENDURE study
Interim data from a randomized placebo-controlled trial of accelerated transcranial magnetic intermittent theta-burst stimulation and adjunctive d-cycloserine for suicidal ideation
Synergistic biobehavioral treatments to reduce depression and compulsivity
Novel therapeutics with entactogenic effects - a new frontier for mood and anxiety disorders?
EMP-01 (R-MDMA) as a next-generation entactogen: Mechanistic rationale and therapeutic potential in social anxiety disorder
Intravenous ketamine improves social anhedonia in patients with treatment-resistant depression and suicidal ideation
Ketamine’s potential for treating loneliness in treatment resistant bipolar depression
Objective measures of empathy: Prosocial learning and mood states
Targeted interventions for suicide prevention
Using intensive, real-time monitoring designs to identify proximal risk factors for suicidal ideation among adolescents
Changes in symptoms of suicidal ideation and related symptoms with tirzepatide in individuals with moderate-to-severe methamphetamine use disorder
Psychosocial interventions for older adults with depression and varying degrees of cognitive functioning after a suicide-related hospitalization
Efficacy and safety of a single dose of psilocybin for chronic active suicidal ideation: Experiences in an open label trial
Improving metabolic health in mental illness: A transdiagnostic approach
Psymetric 2.0: Development, refinement and external validation of clinic-ready cardiometabolic prediction models for young people with psychosis spectrum disorders
Treating psychotropic associated weight gain in individuals with intellectual and developmental disability: A retrospective chart review study
PTSD and diabetes: A two-way street in metabolic and mental health
PMCID: PMC7170451.
Strategies to improve treatment effect detection in MDD trials
Strategies to improve treatment effect detection in MDD trials
Functional connectivity of the striatum as a biomarker of treatment response to KCNQ-targeted agents in depression
Depression and disturbances in circadian rhythms: Pathways for novel treatment development
Towards an international, standardized model psychopharmacology curriculum for psychiatry residency training: A competency-based framework for implementation
The ASCP model psychopharmacology curriculum update
Towards an international, standardized model psychopharmacology curriculum for psychiatry residency training: A competency-based framework for implementation
Towards an international, standardized model psychopharmacology curriculum for psychiatry residency training: A competency-based framework for implementation
RE104. A novel serotonergic psychedelic 4-OH-DIPT prodrug for the treatment of postpartum depression
A new dawn for social anxiety treatment: Clinical advancement of the novel V1aR antagonist, NTX-1472
DT-101 – a novel alpha-amino-3-hydroxy-5-methyl-4-isoxazole receptor (AMPAR) positive allosteric modulator demonstrates favorable tolerability and functional biomarkers in phase 1 healthy volunteer trial
Seltorexant, adjunctive to antidepressants, in adults with major depressive disorder with insomnia symptoms: Phase 3 studies
Ketamine treatment for non-motor symptoms of Parkinson's disease
Forvisirvat (SP-624), a first-in-human SIRT6 activator with an epigenetic mechanism of action, currently in a phase 2b-3 study for the treatment of major depressive disorder
Unlocking medicines for neuropsychiatry by enhancing oral absorption using a lymphatic-targeting prodrug technology
BH-200 (nelivaptan), a vasopressin V1b receptor antagonist, in genetically defined subgroups of MDD: Precision targeting of HPA-axis dysregulation in the OLIVE phase 2 program
Novel oral rapid-acting neuroactive steroid for treatment of postpartum depression: A placebo-controlled phase 3 clinical trial of lpcn 1154a
A randomized, placebo-controlled trial of the fatty acid amide hydrolase inhibitor palmitoylethanolamide in bipolar depression
Prospective replication of an EEG biomarker for predicting changes in attention in ALTO-203, an H3 inverse agonist
Findings from the ASCP presidential task force on psychotropic drug polypharmacotherapy
Underutilized augmenters in polypharmacy regimens: The case for lithium
Rational and irrational psychopharmacology combinations
When to switch versus augment pharmacotherapies
Mondo combo: Do combinations of antipsychotics ever make any sense?
Comorbidity polypharmacy: Simultaneous vs. Successive introduction of co-pharmacotherapies
Safety, tolerability, and drug-drug interaction concerns in polypharmacology regimens
Waking up to excessive daytime sleepiness in psychiatry and how to make wearables work for measuring sleep and activity
Sleep assessments as predictors of health risk and depression
Smartwatch measurements and controlled depression: Comparative analyses on physical activity and sleep
PMCID: PMC9008579. sleep and its utility for mental health and well-being research: The case for longitudinal measurements
Deploying artificial intelligence (AI) and large language models (LLMs) in psychiatry drug development
Designing the next generation of studies of psychedelics for difficult to treat depression
Using neuroimaging to elucidate psychedelic mechanisms of action on brain circuits
Long term outcomes from psilocybin and response to re-dosing for difficult to treat depression
Critical methodological decisions in psychedelic drug trials
Regulatory plenary: AI-based tools in CNS drug development: A regulatory framework for clinical trial applications
ASCP lifetime awardee talk and Nasrallah awardee
The tyranny of the p-value: Effect size matters
A short journey through a 50 years of progress in the treatment of depression
Clinical updates on neurotherapeutics: Disease state
SGAs vs mood stabilizers: The paradigm shift in core treatment for bipolar disorder
An update on bipolar disorder: Evidence, challenges, and solutions
The pharmacologic treatment of schizophrenia: Status report
Exciting new findings from clinical trials in the treatment of post-traumatic stress disorder
Schizophrenia polygenic risk is negatively associated with body mass index in two population cohorts
Retrospective analysis of real-world transition strategies for xanomeline and trospium chloride in adult patients with schizophrenia
Sleep estimation from low-frequency smartphone sensors via Bayesian hidden Markov model
Neural and behavioral evidence from reinforcement learning converge in support of relaxed beliefs under LSD
Augmenting dorsolateral prefrontal cortex-targeted tDCS with cognitive reappraisal in cocaine use disorder
Mixed amphetamine salts and lisdexamfetamine as adjunctive treatment for bipolar depression: Pooled analysis of two randomized controlled trials
Brain-to-brain movie neurofeedback reduces craving in opioid use disorder
33959050; PMCID: PMC8093505.
Evaluating hepatic effects of serial ketamine infusions for treatment-resistant bipolar depression
Drug liking and craving of intravenous ketamine when prescribed for the treatment of mood disorders in a monitored setting: A descriptive analysis
Combined ketamine and cognitive behavioral therapy: Leveraging metaplasticity to enhance outcomes
Repeated ketamine infusions for treatment-resistant bipolar depression: A randomized, midazolam-controlled clinical trial
10.1177/20451253231202723. PMID: 37771417; PMCID: PMC10524067.
AMPA receptor binding potential is reduced in the anterior cingulate cortex of female patients with PTSD
PMID: 31959988.
Durability of TMS treatment for veterans with MDD examined via significant psychiatric events associated with relapse (SPEAR): A proposed new composite outcome measure for high severity/low frequency mental health events
Is brain insulin action implicated in the biology of depression? A pilot neuroimaging study in adolescents
Semaglutide improves health-related quality of life in major depressive disorder independent of mood change: Evidence for metabolic and motivational pathways
Moving beyond sleep: The broader connection between the orexin system and psychiatric disorders
Incorporating novel muscarinic agents for schizophrenia into clinical practice: Overcoming clinical inertia
6736(25)02365-7. PMID: 41763745
AI beyond evil robots: Ensuring transformative means better
Update from federal and other funding agencies
NIAAA update: Focus on the medications development program
Patient-centered comparative effectiveness research
Advancing therapeutics for substance use disorders through nida’s therapeutics development program
PMID: 40395395; PMCID: PMC12089859. update from defense health agency psychological health research portfolio
Updates from veteran health administration (VA) research initiatives
NIMH update
Durability outcomes in treatment resistant depression
Transcranial magnetic stimulation: Durability of anti-depressant response
Durability of vagus nerve stimulation treatment-resistant depression: New, more comprehensive findings from the recover trial
Beyond the acute course: Exploring the durability of ketamine's antidepressant effects in the maintenance phase of treatment
15. PMID: 40834563.
40319349; PMCID: PMC12143125. how durable are acute effects of psilocybin on treatment-resistant depression?
Evolving understandings of psychedelics in clinical research
Understanding psilocybin administration: Dose, participant characteristics, and therapeutic context
Recruiting, retaining, and tailoring psychedelic clinical trials for vulnerable populations
Evaluating the clinical utility of psilocybin therapy versus other psychedelic drug interventions for the treatment of posttraumatic stress disorder
Building collaborative capacity in early career psychopharmacology: Strategies for effective partnerships across academia, industry, and clinical practice
The evolving nature of academic-industry partnerships
PMCID: PMC11000613 take-aways from my experience starting out in clinical psychopharmacology research
10.1056/NEJM1994052633021131530 – 1533 why do we need team science approaches in neurobiological and clinical studies
39171416; PMCID: PMC11652247.
03008-5. PMID: 39054336; PMCID: PMC11272929. development of esketamine. An academic -industry dream collaboration
Are early career clinical researchers in psychiatry an endangered species?
The young investigator as a pluripotent stem cell: The role of industry-academic partnerships in a successful career
Communication and conflict management: Practical tools for effective leadership in research
Advances in depression research: A tribute to Nolan Williams
Understanding and harnessing the opioid effects of ketamine
Non-invasive amygdala neuromodulation in humans with focused ultrasound: Neurobiological and clinical effects in mood, anxiety, and trauma-related disorders
Clinical and neural outcomes of magnesium-ibogaine for traumatic brain injury in special operations forces veterans
Photobiomodulation with near infrared light: A novel treatment for psychiatric disorders
Dose-dependent effects of transcranial photobiomodulation on brain temperature in patients with major depressive disorder: A spectroscopy study
6. PMID: 39370461. Transcranial photobiomodulation for Alzheimer's disease
Transcranial infrared laser stimulation improves cognitive performance and induces a biphasic cerebral perfusion response in remitted bipolar disorder
Uncovering mechanisms of photobiomodulation behind clinical changes: Evidence from neuroimaging
Lessons from transforming the psychiatric healthcare system: How to improve outcomes?
Alignment for progress: A movement to bring change
One expert by experience journey
Challenges of building a learning health system for early psychosis care
Transforming the healthcare system with the bipolar action network
Developing treatments for the non-motor symptoms of Parkinson's disease
AB-300, a novel 5-HT2A/2C agonist, reverses motivational deficits in a tetrabenazine model of Parkinson’s disease apathy
Psilocybin therapy for depression in Parkinson’s disease
Targeting synaptic loss in Parkinson’s disease depression with ketamine
Artificial intelligence: Understanding the present and anticipating the future
Using artificial intelligence and social media data for population mental health surveillance
Assessing AI for clinical care and research
Bridging AI innovation and clinical trial data in psychiatry: Mathematical limits and clinical consequences
What to know about ketamine safety: Patient monitoring, neurotoxicity, and considerations for special patient populations
Racemic ketamine side effects, adverse reactions, and monitoring
Ketamine for depression, but at what cost? Evidence for neurotoxicity from human and animal studies
Use of ketamine for depression in special populations
The discovery and clinical development of (2R,6R)- hydroxynorketamine for depression and pain
From ketamine metabolite to candidate therapeutic: Preclinical discovery of (2R,6R)-HNK relevance to depression treatment
Preclinical development of (2R,6R)-hydroxynorketamine for human clinical evaluation
Clinical development of (2R,6R)-hydroxynorketamine: Ongoing trials in TRD and OCD and phase 1 safety, tolerability, and PK/PD results in healthy volunteers
Evaluation of the (2R,6R)-hydroxynorketamine as a potential clinical useful analgesic agent: Translational experience from preclinical to human study
New and anticipated interventions for perinatal depression
Pathophysiological mechanisms of perinatal depression
Epigenetic biomarkers in postpartum depression and postpartum psychosis
Approved and potential treatments for PPD
Addiction and neuromodulation in pregnancy
The future DSM: Designing a scientific, inclusive, and practical diagnostic manual for modern psychiatry
The future DSM: Designing a scientific, inclusive, and practical diagnostic manual for modern psychiatry
Structure and dimensions subcommittee
The DSM subcommittee on candidate biomarkers and biological factors
Regulatory challenges: Ask the experts
W1. The phase 2/3 gain trial of the first-generation p. gingivalis gingipain inhibitor atuzaginstat in mild-to-moderate probable Alzheimer’s disease: New cerebrospinal fluid biomarker data
W2. Galantamine-memantine combination regulating the kynurenine pathway metabolism in the treatment of post-stroke depression and post-stroke cognitive impairments and prevention of stroke
W3. Dynamic causal modeling of triple-network connectivity varies by suicide attempt history
W4. A review of evidence and an algorithm for use of psychopharmacology in the treatment of tobacco use disorder in behavioral health settings
W5. Evidence from randomized controlled trials in substance use disorders with memantine, galantamine, n-acetylcysteine, and doxazosin/prazosin
W6. Changes in smoking-related outcomes with tirzepatide in individuals with methamphetamine use disorder who smoke
W7. Changes in depressive symptoms with tirzepatide in individuals with moderate-to-severe methamphetamine use disorder
W8. Safety and tolerability of 32-week-long treatment with tirzepatide in individuals with moderate-to-severe methamphetamine use disorder
W9. First dose treatment effects with injectable weekly and monthly buprenorphine (CAM2038) and the relationship between buprenorphine plasma concentrations and withdrawal suppression in participants with opioid use disorder
W10. A new dawn for social anxiety treatment: Clinical advancement of the novel V1aR antagonist, NTX-1472
W11. Treatment patterns among incident and persistent patients with generalized anxiety disorder (GAD)
W12. The impact of comorbid psychiatric disorders on misconducts among incarcerated individuals with attention-deficit/hyperactivity disorder: A preliminary study
W13. The neurochemical and anxiolytic-like effects of centanafadine in preclinical assays in the rat and mouse
W14. Growing trend of stimulant use in young patients misdiagnosed with ADHD: A case-based systematic review
W15. Emotional dysregulation symptom outcomes in adults with ADHD treated with centanafadine: A pooled post hoc analysis of two phase 3 trials
W16. The persistence of neuroepithelial progenitors in neocortical organoids: Impeding accurate models for drug screening in neurodevelopmental disorders
W17. Long-term safety and tolerability of cariprazine in pediatric patients with autism spectrum disorder, bipolar I disorder or schizophrenia: Final results from an open-label study
W18. E2086, a selective orexin receptor-2 agonist: Study for promoting wakefulness in patients with narcolepsy type 1
W19. The complex multi-system symptom inventory (COMSS): A new instrument to assess symptom frequency, impact, and postural dependence across multiple central and peripheral autonomic symptom domains
W20. Static and dynamic disruptions of salience-network flexibility in veterans with comorbid mild TBI and alcohol use disorder
W21. Successful early treatment of anti-n-methyl-d-aspartate receptor encephalitis associated with small cell lung cancer in an elderly male patient: A case report
W22. GH001 efficacy is independent of prior antidepressant treatment failures in treatment-resistant depression: A post hoc analysis of a phase 2b randomized controlled trial
W23. Examining the impact of patient-centered approaches on the assessment and management of cognitive impairment in major depressive disorder
W24. Seltorexant versus quetiapine extended release as adjunctive treatment in major depressive disorder with insomnia symptoms: Phase 3 trial
W25. Benefits of adjunctive vagus nerve stimulation in difficult-to-treat depression: Outcomes of a naturalistic European cohort (RESTORE-LIFE) compared to the USA recover randomized controlled trial
W26. Pooled individual patient data analysis of three phase 2 trials supports vasopressin V1b receptor antagonism (BH-200 250 mg BID) as an antidepressant mechanism for the treatment of major depressive disorder (MDD)
W27. Genetically defined subgroup analysis reveals differential response to vasopressin V1b antagonism in patients with MDD pre-exposed to antidepressant in the current episode: Post-hoc analysis of the phase 2 OLIVE trial
W28. Characteristics of depression episodes to inform real-world health states for major depressive disorder and treatment-resistant depression
W29. Longitudinal profiling of treatment trajectories in SSRI-anchored MDD using agentic AI
W30. Dimensions of psychedelic experience predicting antidepressant response to psilocybin across diagnoses
W31. Anxious depression as predictor of clinical outcomes in treatment-resistant depression (ASCERTAIN-TRD)
W32. Neuroactive steroid changes pre-and post-ketamine during a double-blind, crossover clinical trial: An exploratory study
W33. Association of major depressive disorder with insomnia symptoms with healthcare resource use and cardiovascular and metabolic conditions – analysis of national health and nutrition examination survey
W34. Esmethadone (REL-1017) in patients with antidepressant tachyphylaxis: A post hoc efficacy analysis in a pre-randomization–defined subgroup
W35. Preclinical behavioral and pharmacological characteristics of TN-001, a novel, non-hallucinogenic neuroplastogen for the treatment of major depressive disorder
W36. Metabolic profile of adjunctive lumateperone 42 mg in major depressive disorder: A pooled analysis of 2 randomized, placebo-controlled trials
W37. Lumateperone 42 mg in major depressive disorder: Demographic and clinical subgroups efficacy analysis in a phase 3 randomized placebo-controlled trial
W38. Efficacy of lumateperone 42 mg for the treatment of major depressive disorder: Analysis of demographic and clinical subgroups in a phase 3 randomized placebo-controlled trial
W39. Psychopharmacology of ENX-104: A potent dopamine (DA) D2/D3 receptor antagonist for the treatment of neuropsychiatric disorders associated with anhedonia
W40. Impact of GH001 on depressive symptoms, anxiety, and quality of life in treatment-resistant depression: Results from a phase 2b trial
W41. Rapid and sustained improvement in anhedonia following inhaled mebufotenin (GH001) treatment in patients with treatment-resistant depression
W42. Effects of dextromethorphan-bupropion (45mg/105mg) in participants with major depressive disorder and anxious distress
W43. HJ-006: A non-hallucinogenic synaptogenic compound with rapid and sustained antidepressant efficacy
W45. Psychomotor disturbance as a predictor of treatment response in mood disorders: A systematic review
W46. The monotherapy antidepressant pipeline problem: Only 8 approvals out of 28 attempts in the last 25 years
W47. Early response to psilocybin in adults with treatment-resistant depression as a predictor for antidepressant efficacy
W48. Early motivational and hedonic responses to antidepressants in major depressive disorder: A real-world evidence study
W49. Real-world evidence of the clinical and preference impact of a prescription digital therapeutic for major depressive disorder: An ongoing prospective study in an academic health system
W50. Anxiolytic effects of dextromethorphan-bupropion (45mg/105mg): Post hoc analyses across trials in major depressive disorder
W51. Multimodal identification of neurobiological subtypes associated with ketamine response in treatment-resistant depression using NETRAAI
W52. Orexin 2 receptor agonists as a potential therapeutic approach to the treatment of sleep-wake disturbance, fatigue, and cognitive deficit in neuropsychiatric disease
W53. A novel disease-modifying strategy for narcolepsy type 1 – preclinical rationale and development roadmap for the Doxa platform
W54. Targeted eligibility review can decrease the number of inappropriate participants enrolled in clinical trials
W55. IMPACT-EXT: Evaluating the durability and redosing of TSND-201 (methylone) for the treatment of PTSD
W56. Safety, pharmacokinetics, and pharmacodynamics of MSD-001 after single dosing in healthy adults: A randomized, double-blind, placebo-controlled study
W57. Blinding integrity in psychedelic randomized controlled trials: A systematic review
W58. Unlocking medicines for neuropsychiatry by enhancing oral absorption using a lymphatic-targeting prodrug technology
W59. A randomized, placebo-controlled trial of the fatty acid amide hydrolase inhibitor palmitoylethanolamide in bipolar depression
W60. Efficacy, safety and tolerability of lysergic acid diethylamide for the treatment of depressive symptoms: A meta-analysis and systematic review
(CRD420251063539).
W61. Beyond mood: Broader psychological benefits of IV ketamine for major depressive disorder
W62. The complex diagnostic profile of psychiatric outpatients presenting for the treatment of bipolar depression
W63. Sodium-glucose cotransporter-2 inhibitors reduce suicidality, all-cause mortality, and hospitalization in bipolar disorder: A cohort study of 1.23 million adults
W64. Preclinical efficacy of concomitant administration of novel GSK3β inhibitor 4MT-A and lithium orotate
W65. The neurobiological effects of psilocybin in treatment resistant bipolar depression: Protocol and interim analysis of clinical outcomes
W66. Effect of cariprazine treatment on sleep and mood symptoms in patients with bipolar I depression and baseline sleep disturbance: Post hoc analysis of three randomized placebo-controlled clinical trials
W67. An open-label, two-arm study of ketamine’s effects on fluid cognition in mood disorders with and without psychosis
W68. Tirzepatide precipitating acute lithium toxicity in stable bipolar I disorder
W69. Effects of cariprazine on symptoms of anxiety: A pooled post hoc analysis of double-blind clinical trials in patients with depression
W70. Real-world impact on anxiety symptoms of cariprazine as adjunctive treatment in major depressive disorder or monotherapy in bipolar I disorder
W71. Antipsychotic switching among patients with bipolar I depression after initiating cariprazine vs lumateperone: A real-world claims-based study
W72. Comparative efficacy of bupropion vs selective serotonin reuptake inhibitors in antidepressant-naive, obese patients with major depressive disorder
W73. Effect of psychedelic therapies on sleep in psychiatric disorders: A systematic review and meta-analysis of randomized clinical trials
W74. Impact of seltorexant on cognitive performance of adults with major depressive disorder with insomnia symptoms
W75. Intermittent white light at 60 Hz as a potential neurostimulation approach for depression: Effects on EEG activity and safety in healthy human volunteers
NCT07111390). W76. safety and efficacy of full and half-dose neuronavigated accelerated theta burst TMS in treatment-naïve adolescent depression
W77. Real-world evidence from legal psilocybin-assisted services in Oregon: Psychedelic preparedness and experiential predictors of mental health outcomes
W78. Protocol for real world safety and effectiveness study of psilocybin therapy
W79. Real-world experience and impact of fatigue in narcolepsy and idiopathic hypersomnia from the ASPIRE survey study
W80. Activation of σ1R and 5-HT2A pathways modulates neuroinflammation, glial repair programs, and BBB responses in demyelinating CNS models
W81. Examining the impact of trauma on ketamine's efficacy in bipolar I/II depression: A secondary analysis from a randomized, midazolam-controlled trial
W82. Real-world persistence on olanzapine/samidorphan versus other oral second-generation antipsychotics in patients with schizophrenia
W83. Using artificial intelligence/machine learning and real-world data to identify patients with schizophrenia for whom an aripiprazole monohydrate LAI is likely to be a favorable treatment option
W84. Endocrine biomarkers of suicide risk in schizophrenia
W85. Clozapine's antagonism is robust against known DRD2 mutations
W86. Impact of negative symptoms on healthcare resource utilization and costs in schizophrenia: A real-world data analysis
95% CI: 0.99-1.39; P=0.06).
W87. Onset, duration, and incidence of adverse events by dose and titration schedule of xanomeline and trospium chloride
W88. SUVN-L1101142, a muscarinic M4 positive allosteric modulator (M4 PAM) for the treatment of psychosis-related disorders and condition
W89. Occurrence of urinary retention-related adverse events with xanomeline and trospium chloride: Results from the 52-week, open-label EMERGENT-5 trial
W90. Olanzapine and samidorphan in adults with schizophrenia or bipolar I disorder: Updated review of clinical data
W91. Longitudinal trends in antipsychotic polytherapy and associated outcomes in schizophrenia
W92. Efficacy and safety of xanomeline and trospium chloride for mania in bipolar disorder: Design of the BALSAM-1 and BALSAM-2 trials
W93. Real-world impact of olanzapine and samidorphan on rates of relapse among young adults with schizophrenia or bipolar I disorder
W94. Translational evidence for dopaminergic alteration of basal ganglia functional connectivity in persons with schizophrenia
W95. Memantine for the treatment of primary negative symptoms in schizophrenia: A meta-analysis of randomized controlled trials
W97. Risk of suicide attempt in newly diagnosed ADHD with and without stimulant treatment within three months of diagnosis
W98. Novel oral rapid-acting neuroactive steroid for treatment of postpartum depression: A placebo-controlled phase 3 clinical trial of lpcn 1154a
W99. Acute treatment of postpartum psychosis: An update from the Massachusetts general hospital postpartum psychosis project
W100. RE104: A novel serotonergic psychedelic 4-OH-DIPT prodrug for the treatment of postpartum depression
W101. Use of long-acting injectable antipsychotics in forensic psychiatry: A multi-site Canadian study
W102. Suicide risk of third-generation antipsychotics in persons with schizophrenia and schizoaffective disorders: A systematic review and meta-analysis
W103. Aripiprazole once-monthly for patients living with schizophrenia: Number needed to treat, number needed to harm, and likelihood to be helped or harmed
W105. Machine learning detection of arousals from at-home sleep EEG device demonstrates comparable performance to expert raters in sleep disorders with and without antidepressant use
W106. Higher polygenic risk for mitochondrial dysfunction is associated with lower cerebral blood flow in youth with bipolar disorder
W107. Choroid plexus volume as a biomarker of ketamine-related improvement in irritability in adults with major depressive disorder
W108. Challenges and strategies for training and retaining the next generation of physician scientists in psychiatry during residency and fellowship
W109. Applying scientific and operational insights from prior clinical trials to optimize efficacy signal detection in a proof of concept trial with KYN-5356 in cognitive impairment associated with schizophrenia
W110. Initial psychometric properties of the anhedonia interview rating scale clinician (AIRS) and self-report (AIRS-SR) among potential psychiatry study participants
W111. A first-in-human study to evaluate safety, pharmacokinetics and pharmacodynamics of KYN-5356, a first-in-class inhibitor of kynurenine aminotransferase II (KAT-II)
W112. Demographic and clinical characteristics of participants receiving COMP360 psilocybin treatment for treatment-resistant depression across two pivotal phase 3 trials
W113. Closing the care gap: Embedding PTSD screening in primary care workflows
W114. Durability of efficacy and safety of COMP360 psilocybin for treatment-resistant depression (TRD) across 26 weeks in a double-blind, randomized, controlled phase 3 study
W115. Elunetirom, a first-in-class, brain-targeting, antidepressant candidate in Ph2 development, triggers robust bioenergetic and neuroplastic improvements in preclinical studies
W116. Lysergide tartrate (LSD; DT120) safety profile from phase 1 and phase 2 clinical studies
W117. Rational deprescribing: ASCP expert consensus for mood disorders
W118. The association between ketamine and esketamine and urological symptoms: Reports to the food and drug administration adverse event reporting system (FAERS)
W119. Efficacy and safety of xanomeline/trospium chloride during transition from atypical antipsychotics in participants with stable schizophrenia symptoms in EMERGENT-5
W120. Silence is golden: Speech production during psilocybin administration sessions for the treatment of post-traumatic stress disorder
W121. A novel interactive digital learning tool (Discover TD®) for psychiatry resident training on diagnosis and treatment of drug-induced movement disorders
W122. Impact of a three-part online educational webinar series on psychiatrists’ knowledge, competence, and confidence in diagnosing and managing tardive dyskinesia
W123. Identifying and predicting symptom trajectories in a blended hybrid digital mental health clinic
W124. Cognitive impairment in major depressive disorder: A patient-prioritized target for functional recovery
W125. Evaluation of VEDAI across clinical psychiatry: A blinded psychiatrist-rated study
W126. Pharmacological validation of neurokit as a portable, sensitive and reproducible test battery in early clinical central nervous system (CNS) drug development
W127. Modeling continuous-time network dynamics of passive sensing and ecological momentary assessment data to characterize treatment response in digital mental health care
T1. Ketamine treatment for non-motor symptoms of Parkinson's disease
T2. Effects of itraconazole and carbamazepine on the pharmacokinetics of remlifanserin (ACP-204) in healthy adults
T3. Correlation of plasma p-tau217 and CSF p-tau181 with clinical diagnosis of Alzheimer’s disease: A cross-sectional study of 1,766 participants in the Alzheimer’s disease neuroimaging initiative
T4. Assessing community pharmacist preparedness to implement methadone dispensing and observation
T5. Understanding kratom’s effects and abuse potential: Design of the first FDA-funded human study
T6. Menstrual phase-driven frontal white matter microstructural dynamics track progesterone and craving variability in women with substance use disorders
T7. Semaglutide for the treatment of opioid use disorder: Interim analysis of a pilot randomized controlled trial
T8. Office-based treatment retention among patients with opioid use disorder and recent fentanyl use: Extended-release injectable buprenorphine vs sublingual buprenorphine
T9. Real-world utilization trends of weekly and monthly injectable buprenorphine (CAM2038) in the United states during the era of high potency synthetic opioids
T10. The pharmacokinetic properties and target engagement effects of the novel serotonin transporter modulator, SNTX-2643, in healthy adults
T11. Efficacy and safety of ulotaront in adults with generalized anxiety disorder: Results from a phase 2/3 randomized placebo-controlled trial
T12. Mazindol IR/SR: A 50-year legacy repositioned as a first-in-class orexin–monoamine modulator for ADHD and arousal-related disorders
T13. Comprehensive multitarget strategy for type 1 diabetes and associated neurological/sleep disorders (DANS): Integrating stem-cell-derived islet replacement, immune modulation, and neuro-circadian therapeutics
T14. Investigating the safety, efficacy, and tolerability of adjunctive cariprazine treatment to psychostimulants in adults with ADHD: A preliminary study
T15. ASRS outcomes across core and expanded symptom domains after 6 weeks of centanafadine treatment in adults with ADHD: A pooled post hoc analysis of two phase 3 trials
T16. Executive function symptom outcomes in adults with ADHD treated with centanafadine: A pooled post hoc analysis of two phase 3 trials
T17. Pathophysiological analysis of autism spectrum disorder focusing on peripheral blood macrophages
T18. Psychotropic prescribing trends within the Texas juvenile justice department from 2016 to 2024
T19. Sleep architecture in participants with insomnia disorder characterized by phenotype: Objective short sleep or objective normal sleep
T20. Psilocybin-assisted psychotherapy for cluster b personality disorders and comorbid treatment-resistant depression
T21. Pharmacotherapies for co-occurring stimulant use disorder and ADHD: A network meta-analysis
T22. Effects of glucagon-like peptide 1 receptor agonists (GLP-1RAs/GLP-1s) integration in patients utilizing antipsychotics
T23. Prevalence of psychotropic medication use among patients with chronic and immune-mediated diseases: A real-world analysis using Epic Cosmos
T24. Prospective replication of an EEG biomarker for predicting changes in attention in ALTO-203, an H3 inverse agonist
T25. BH-200 (nelivaptan), a vasopressin V1b receptor antagonist, in genetically defined subgroups of MDD: Precision targeting of HPA-axis dysregulation in the OLIVE phase 2 program
T26. A phase 2 clinical trial exploring efficacy and safety of the vasopressin V1b antagonist BH-200, a treatment for MDD, evaluating the performance of a genetic classification tool to identify a subset of patients with larger improvement
T27. Forvisirvat (SP-624), a first-in-human SIRT6 activator with an epigenetic mechanism of action, currently in a phase 2b-3 study for the treatment of major depressive disorder
T28. Effect of ketamine on individual symptoms of depression in a randomized controlled trial of ketamine for treatment-resistant depression
T29. Effects of solriamfetol on neuropsychological outcomes in patients with obstructive sleep apnea in the real-world surwey study
T30. Metabolic profiles of participants with major depressive disorder with insomnia symptoms in a phase 3 trial of seltorexant versus quetiapine extended release as adjunctive therapy
T31. Decrease in negative mood and increase in positive mood during 12 months of vagal nerve stimulation
T32. Use of a prospective lead-in study to enhance eligibility and reduce screen failure in major depressive disorder trials
T33. Metabolic burden, inflammation, and esketamine efficacy in treatment-resistant major depressive episodes
T34. Real-world clinical outcomes of patients switching to treatment with dextromethorphan-bupropion (45 MG/105 mg)
T35. Efficacy and safety of esmethadone (REL-1017) in patients with major depressive disorder and inadequate response to standard antidepressants: Findings from two early-terminated phase 3 trials
T36. Lumateperone versus other adjunctive atypical antipsychotics for major depressive disorder: A network meta-analysis of comparative efficacy and safety
T37. A phase Ib study evaluating safety, preliminary efficacy, and putative biomarkers of neuroplasticity for the novel neuroplastogen zalsupindole (DLX-001) in major depressive disorder
T38. Real-world effectiveness of intravenous ketamine on depressive symptoms, suicidal ideation and functional impairment in adults with mood disorders
T39. Evaluating the association between antidepressant efficacy and dissociation with ketamine in treatment-resistant bipolar depression (TRBD)
T40. Adjunctive lumateperone 42 mg treatment in major depressive disorder: Efficacy across patient-reported depression symptoms
T41. First onset and duration of treatment-emergent adverse events in patients with major depressive disorder treated with adjunctive lumateperone 42 mg: A pooled analysis of 2 randomized placebo-controlled trials
T42. Remission with lumateperone 42 mg adjunctive to antidepressant therapy in patients with major depressive disorder: Analysis of short-term and long-term trials
T43. Peripheral biomarker reliability in major depressive disorder: A meta-analysis of S100B
T44. Evaluating the abuse liability of ketamine in the treatment of mood disorders: A systematic review
T45. Patterns of real-world antipsychotic switching after initiating adjunctive cariprazine or lumateperone in adults with major depressive disorder
T46. Costs associated with adjunctive atypical antipsychotic– related weight gain among patients with major depressive disorder: An economic model using numbers needed to harm
T47. Preclinical evaluation of ropanicant, a nicotinic acetylcholine α4β2 receptor antagonist in animal models of depression
T48. Ropanicant (SUVN-911), an α4β2 nAChR antagonist: A phase 2b, randomized, double-blind, placebo-controlled, parallel-group study, evaluating the efficacy and safety of ropanicant in patients with major depressive disorder (MDD)
T49. Concurrent oral antidepressant use and clinical outcomes from intravenous ketamine or intranasal esketamine in a real-world sample
T50. Psilocybin treatment for chronic neuropathic pain and depression
T51. Convergent validity and treatment responsiveness of the patient-rated depression checklist (PRDC)
T52. An investigation of the putative antidepressant mechanisms of ketamine, Reelin, and mu opioid receptor agonists in rats and ipsc-derived cerebral organoids exposed to chronic stress
T53. A language-derived affective sentiment dimension of ketamine response in depression
T54. Interpreting psychiatric digital phenotyping data with large language models: A preliminary analysis
T55. A simulation-based framework for characterizing risk in clinically-deployed large language models
T56. AI-enabled patient-derived neuronal models for mechanism-guided antidepressant selection in major depressive disorder
T57. Sustained pharmacodynamic effects of esketamine on cortical excitability and resting-state brain activity: A randomized, placebo-controlled trial
T58. ALTO-207, a fixed-dose combination of pramipexole and ondansetron, suggests efficacy in treating major depression: Findings from a randomized, double-blind phase 2a trial
T59. Effects of alixorexton on patient-reported disease severity, cognitive functioning, and fatigue in patients with narcolepsy type 1: Results from the phase 2 VIBRANCE-1 study
T60. Safety and efficacy results from the phase 2 VIBRANCE-1 study of the orexin 2 receptor agonist alixorexton in patients with narcolepsy type 1
T61. The use of magnetoencephalography (MEG) in a first-in-human trial to demonstrate the functional consequences of target engagement by DT-101, a novel AMPA receptor positive allosteric modulator
T62. Cross trial identification of a predictive enrichment subgroup for esmethadone (rel 1017) in major depressive disorder using explainable machine learning
T63. Prediction of human pharmacokinetic profiles of Glyph platform prodrugs using animal and human data via a semi-mechanistic pharmacokinetic model
T64. Evaluating potential abuse-related adverse events in clinical studies of psychedelics and novel central nervous system active drugs to inform labeling and scheduling recommendations: Issues, methods, and recommendations
T65. DT-101 – a novel alpha-amino-3-hydroxy-5-methyl-4-isoxazole receptor (AMPAR) positive allosteric modulator demonstrates favorable tolerability and functional biomarkers in phase 1 healthy volunteer trial
T66. Using artificial intelligence/machine learning and real-world data to identify patients with early stage bipolar-I disorder for whom an aripiprazole monohydrate LAI is likely to be a favorable treatment option
T67. Do non-DSM criteria enhance the validity of the DSM-5 mixed features specifier in depressed patients?
T68. Multifocal negative affect: The prevalence and clinical profile of psychiatric outpatients who are depressed, anxious and irritable
T69. The McIntyre and Rosenblat rapid response scale (MARRRS): A psychometric evaluation of patients with treatment-resistant bipolar depression
T70. Changes in sleep patterns with psilocybin-assisted psychotherapy: An exploratory analysis of a randomized clinical trial for treatment-resistant depression
T71. Psilocybin for anhedonia: A systematic review of clinical and preclinical evidence
T72. Don’t let AI make you moody: Assessing racial bias in large language models’ clinical decision-making in mood disorders
T73. Evaluating the potential risk of ketamine-induced hepatotoxicity in the treatment of mood and anxiety disorders: A systematic review
T74. Cognitive outcomes following serial ketamine infusions in treatment-resistant bipolar I/II depression: Results from a randomized, midazolam-controlled trial
T75. A pilot study of sodium-glucose cotransporter-2 (SGLT2) inhibitor empagliflozin in major depressive disorder
T76. Efficacy of cariprazine for anhedonia symptoms: A pooled analysis of patients with major depressive disorder and bipolar I depression
T77. Differential effects of transcranial photobiomodulation on functional network reorganization across clinical populations
T78. Comparison of the efficacy of neuromodulation therapies in schizophrenia: A systematic review and network meta-analysis
T79. Harmonizing adverse event criteria to improve CNS-related safety and abuse signal detection in clinical trials
T80. Real-world experience and impact of cognitive impairment in narcolepsy and idiopathic hypersomnia from the ASPIRE survey study
T81. A head-to-head assessment of VMAT2 target occupancy of once-daily valbenazine compared to deutetrabenazine extended release
T82. Opioid use in patients with fibromyalgia: A retrospective claims analysis
T83. Complications of an abrupt switch from a full antagonist to a partial D2 agonist
T84. IMPACT-2: A phase 2 randomized, dose-response trial of TSND-201 (methylone) for the treatment of PTSD
T85. Symptoms of post-traumatic stress disorder in individuals with moderate-to-severe methamphetamine use disorder and changes with tirzepatide treatment
T86. A systematic literature review on anti-psychotic utilization in minority populations and key clinical considerations
T87. DT120 (lysergide, LSD): Assessing the potential risk of cardiac valvulopathy after chronic dosing in rats
T88. Real-world treatment patterns in manic/mixed bipolar I disorder: A US retrospective cohort study
T89. ML-007C-MA, a novel investigational M1/M4 muscarinic agonist in phase 2 development for the treatment of schizophrenia and Alzheimer’s disease psychosis
T90. Efficacy of xanomeline and trospium chloride across symptom domains in adults with schizophrenia: Results from the 52-week, open-label EMERGENT-5 clinical trial
T91. The metabolic-cognitive pathway in schizophrenia: Examining fasting glucose, lipids, and blood pressure as predictors of cognitive impairment and dementia risk
T92. Inpatient initiation of the long-acting injectable antipsychotic aripiprazole lauroxil for the treatment of acute exacerbations of schizophrenia
T93. Safety and efficacy of aripiprazole lauroxil in an outpatient setting after initiation during hospitalization for an acute exacerbation of schizophrenia
T94. LB-102 for acute schizophrenia in adults: Results from the phase 2 NOVA1 clinical trial, focused on PANSS total score responder and CGI-S remitter rates
T95. Role of GLP-1 receptor agonists in managing antipsychotic-related metabolic dysfunction and weight gain
T96. Real-world use of xanomeline and trospium chloride in schizophrenia: Patient characteristics, treatment patterns, and outcomes
T97. Real-world comparison of olanzapine/samidorphan vs olanzapine: An assessment of treatment patterns and acute care events among patients with schizophrenia or bipolar I disorder
T98. Real-world outcomes and psychological predictors in an 8-week hybrid digital clinic for depression and anxiety
T99. Resting-state EEG signatures of suicidal ideation severity and intensity in treatment-resistant depression: Preliminary baseline data from two ongoing clinical trials
T100. Attitudes toward artificial intelligence clinical decision support in psychiatry training: Current evidence and future directions
T101. The national pregnancy registry for psychiatric medications: Risk of major malformations following fetal exposure to second generation antipsychotics
T102. Pregnancy outcomes after first-trimester exposure to vortioxetine: Prospective outcomes from the MGH national pregnancy registry for psychiatric medications
T103. Risk of major malformations following first trimester exposure to cariprazine: Preliminary data from the MGH national pregnancy registry for psychiatric medications
T104. Artificial intelligence–assisted participant recruitment for psychiatric clinical trials: A comparative evaluation of lead quality and engagement
T105. Active and passive digital phenotyping to measure outcomes in a 12-month study of xanomeline/ trospium chloride in schizophrenia: Longitudinal prediction of total changes with early levels of physical activity
T106. Exosomes and a novel mitochondrial mechanism of epigenetic regulation of brain plasticity in treatment resistant depression
T107. Perspectives of nurse practitioners and physician associates on presenting long-acting injectables to adults with schizophrenia: A Delphi panel study
T108. A novel, brain penetrant KAT-II inhibitor, KYN-5356, reduces brain kynurenic acid levels and enhances glutamatergic and cholinergic transmission
T109. Racial differences in antidepressant initiation and outcomes after a one-time psychiatric consultation: A mixed-methods study
T110. Efficacy and safety of COMP360 psilocybin for treatment-resistant depression (TRD) in two phase 3 double-blind randomized controlled studies
T111. Esketamine nasal spray for relapse prevention in patients with treatment-resistant depression: A post hoc analysis of predictors of relapse in placebo-treated patients in SUSTAIN-1
T112. Validation of the neurokit platform for central nervous system pharmacodynamic assessment in healthy volunteers
T113. Connectedness as a mechanism of change in psilocybin-assisted cognitive behavioral therapy
T114. Next-generation pharmacotherapies for mood and anxiety disorders: A comprehensive review of phase II/III drug development across diverse mechanisms
T115. Open-label, randomized study to assess safety and efficacy of slow and accelerated switching to xanomeline/trospium from standard of care atypical antipsychotics in participants with schizophrenia
T116. From nightmares to depression: Age-stratified neuropsychiatric effects of montelukast
T117. Improvement of predominant negative symptoms in patients with schizophrenia on paliperidone palmitate 6-month long-acting injectable: Post-hoc analysis over 3 years
T118. Efficacy of sublingual dexmedetomidine in the home setting for reduction in agitation across baseline severity of symptoms in patients with schizophrenia or bipolar disorder
T119. Long-term metabolic and cardiovascular safety and tolerability with xanomeline and trospium chloride: Pooled results from EMERGENT-4 and EMERGENT-5
T120. Schizophrenia-related hospitalization history before long-acting injectable antipsychotic initiation and its association with subsequent adherence and hospitalizations among dual-eligibles: The critical period study
T121. Outcomes in depression symptomatology with high and low levels of suicidal ideation
T122. Real-world safety and effectiveness of lurasidone in Chinese children and adolescents with schizophrenia: A post-hoc analysis of a post-marketing surveillance study
T123. Real-world evidence of clinical treatment response following intravenous racemic ketamine versus intranasal esketamine in adults with major depressive disorder
T124. Multiclass environmental toxicants found in cerebrospinal fluid (CSF) and plasma samples from pregnant women: Potential associations with postpartum depressive symptoms
T125. Continuous multimodal passive monitoring of depressive symptoms via smartphone: Clinical validation of a novel digital health technology
T126. Comparable symptom improvement with electroconvulsive therapy and esketamine in transgender and gender non-conforming adults with treatment-resistant depression
CIAS drug development – is it time for a revolution?
Exploring mitochondrial disturbances in neurodevelopmental disorders
Moderator
Bringing pharmaceutical innovation back to europe: challenges, opportunities and the path forward
CA27 – Current practices in the management of psychiatric patients: how does psychotherapy fit in?
CA01.01. Is this ever going to end? Meta-research in the age of endless evidence
CA03.00. Bridging psychiatry and dentistry: new perspectives on mental health and oral health
CA11.01. Beyond the headlines: psychopharmacology, mental health and the media
CA12.01. From big data to causal insight: rethinking neurodevelopmental risk across the lifespan
CA13.01. Large language models in clinical practice
CA14.01. Tryptophan metabolism: novel targets and biomarkers towards personalized neuropsychopharmacology
CA15.01. Modern pharmacovigilance transforms how we detect emerging drug safety concerns
CA16.01. How to survive the valleys of death in translation: innovative pharmacology in psychiatry
CA18.01. Lost in translation: how to interpret data from MDD clinical trials and observational studies to inform clinical practice?
CA19.01. Stress in the brain: toward objective markers and personalized interventions, with insights from AI
CA22.01. How do we define resilience in animals, and how can we measure it?
CA24.01. In discussion with the ECNP Neuropsychopharmacology Award Winner: negative symptoms in schizophrenia - from biology to clinical practice
CA25.01. To chat or not to chat? Can conversational AI harm mental health?
CA29.01. From variants to biology in Neurodevelopmental Psychiatry
CA33.01. Is ADHD on the rise in children and/or adults?
CD02.01. Parenthood and academic careers: navigating leadership and life transitions in research
CD03.01. The ABCs of the peer-review process
CD04.01. Showing the right story: how to design scientific visualizations for effective research communication
CD04.02. Showing the right story: how to design scientific visualizations for effective research communication
CS01.03. Interactive block 1: Difficult to treat OCD
CS01.06. Interactive block 2: Difficult to treat depression
CS03.05. Interactive block 2: The drug worked — or did it?: A staged go/no-go case in translational neuropsychopharmacology
E01.01. Tourettes in childhood: important considerations in diagnosis
E01.02. Neuropathophysiology and clinical treatment of Tourette Syndrome
E02.01. Prevention and early intervention as pillars of modern psychiatric care
E03.01. Multivariate analysis of immune-molecular profiles for patient stratification in psychotic and affective disorders
E03.02. Multimodal measures of inflammation in early-phase psychosis spectrum disorders
E04.02. Neurobiology of chronic pain and comorbid mental health disorders - From single cells to networks to behaviour
E05.01. A critical review of computational modelling in psychiatry
E06.01. Arts-based strategies to support mental health
E06.02. Translating music therapy to clinical practice for mental health
E07.01. Long-term effect of ADHD medications on academic achievement
E07.02. Long-term safety of methylphenidate: sleep, growth, and adverse events in children with ADHD
EI.02. An unexpected journey: becoming a clinical academic psychiatrist
EP01-1001. Delta-9-tetrahydrocannabinol vaping in mice: pharmacokinetic validation and structural, metabolic and behavioural outcomes
EP01-1002. Translational markers of adolescent vulnerability to behavioural addictions in the era of generative artificial intelligence
EP01-1003. When alcohol disinhibits: neurobiological mechanisms of paradoxical behavioral dysregulation and suicidal behavior in mania a potu
EP01-1004. When control becomes reward: an integrative starvation-driven addiction-like model of anorexia nervosa
EP01-1005. The role of consultation-liaison psychiatry in the management of patients with alcohol use disorder and alcohol related gastrointestinal complications
EP01-1006. Attention deficit hyperactivity disorder and alcohol use disorder: from neurodevelopmental risk to clinical comorbidity
EP01-1007. Delayed and inadequate thiamine treatment leading to korsakoff syndrome: a clinical and therapeutic pitfall
EP01-1008. The family factor: examining parental personality disorders in substance use disorders
EP01-1009. GLP-1 receptor agonists: a novel therapeutic approach for alcohol use disorder?
EP01-1010. Ketamine attenuates cocaine-associated memory reactivation through astrocyte-dependent mechanisms in the nucleus accumbens
EP01-1011. Social, psychological and biological determinants of risk behaviors among adolescents: a Tunisian cross-sectional study
EP01-1012. Psychedelics in the neurobiology of addictive behaviours: from recreational use to therapeutic applications
EP01-1013. Accumulation of risk factors and transition to psychosis: clinical case of a high-risk individual
EP01-1014. A rat model of addiction and withdrawal syndrome and the effect of D2/5-HT3 receptor modulation
EP01-1015. Effects of pyroglutamyl dipeptides on animal behaviour in rats
EP01-1016. Hypogonadism induces depressive-like behaviour and increases astrocytic expression, whereas hyperestrogenism prevents these effects: evidence from two pubertal rat models
EP01-1017. A systematic multilevel analysis of age-dependent behavioural decline using data from the International Mouse Phenotyping Consortium
EP01-1018. Interplay between anorexia nervosa, anxiety and myasthenia gravis in adolescence: a case report
EP01-1021. Functional impairment is independently associated with probable generalised anxiety disorder: a real-world outpatient study in Japan
EP01-1022. A case of preventable surgical intervention: the effect of low-dose aripiprazole in an adolescent with trichotillomania and trichophagia
EP01-1023. Mechanisms linking chronic prostatitis/chronic pelvic pain syndrome with anxiety and depression: a scoping review
EP01-1024. Functional recovery in generalised anxiety disorder: the utility of venlafaxine
EP01-1025. Digital phenotyping signatures of impending psychotic relapse: a machine learning approach using smartphone-derived behavioural data
EP01-1026. Can artificial intelligence detect medical conditions mimicking psychiatric disorders sooner and prevent diagnostic delays
EP01-1027. Leveraging large language models to extract social determinants from electronic health records to assess risk of acute psychiatric crisis
EP01-1028. Artificial intelligence in suicide risk prediction: clinical applicability and ethical considerations
EP01-1029. Immune dysregulation in major depressive disorder: biomarker heterogeneity, sexual dimorphism, and clinical manifestations
EP01-1031. Limited associations between salivary cytokines and depressive symptoms in university students
EP01-1032. Real-world feasibility and clinical engagement of a digital remote monitoring device in routine psychiatric care for mood disorders
EP01-1033. Latent behavioural states obtained from passive digital phenotyping and their clinical characterisation
EP01-1034. Using passive smartphone sensing to assess circadian rhythms in people at-risk of and with severe mental illness: a systematic review
EP01-1035. Unstructured internet use and sleep deprivation in adolescents: a cross-sectional study of high school students
EP01-1036. Late-onset anorexia nervosa and Alzheimer’s disease: Could this case reflect a prodromal process?
EP01-1037. Serotonergic regulation of appetite: 5-HT2C receptors in fluoxetine-ınduced weight change
EP01-1038. Exploring the role of ketamine in eating disorders: a review of emerging evidence
EP01-1039. Avoidant/restrictive food intake disorder after single anastomosis sleeve ileal bypass: a case report
EP01-1040. Use of lisdexamfetamine in binge eating disorder: recommendations and current evidence
EP01-1041. Literature review of suicide risk in athletes and individuals with eating disorders
EP01-1042. Profile psychiatric disorders center for human sciences, letters and arts students treated, university outpatient clinic
EP01-1043. Evaluation of early maladaptive schemas and schema modes in genitopelvic pain/penetration disorder
EP01-1044. Glucagon-like peptide-1 receptor agonists and risk of dementia: a nationwide new-user active-comparator study
EP01-1045. Impulse control at stake: a case of gambling disorder linked to aripiprazole
EP01-1046. Belief beyond sensation: olfactory reference disorder following post-COVID anosmia
EP01-1047. Disentangling symptom dimensions in obsessive–compulsive disorder through objective physical activity and sleep metrics
EP01-1048. Secondary adrenal insufficiency mimicking treatment-resistant depression in an elderly patient: a case of a pituitary macroadenoma
EP01-1049. Salivary microbiota and epigenetic regulation in major depressive disorder: a protocol to explore non-invasive biomarkers
EP01-1050. Bridging the gap in hiv care: a consultation–liaison psychiatry experience
EP01-1051. Malignant catatonia with systemic inflammation: diagnostic and therapeutic challenges in differentiating NMS and neurosarcoidosis
EP01-1052. Temporal relationship between multiple sclerosis relapses and mood episodes in bipolar disorder: a case report
EP01-1054. Depression postpartum
EP01-1055. Pharmacogenetic variability and response to intranasal esketamine in treatment-resistant depression: insights from a real-world study
EP01-1056. LB-102 in patients with bipolar I disorder experiencing a major depressive episode: Phase 2, double-blind, placebo-controlled trial design (ILLUMINATE-1)
EP01-1057. Adjunctive intranasal esketamine and changes in anhedonia in treatment-resistant depression: preliminary real-world evidence
EP01-1058. Differentiating hormone-induced mania from bipolar disorder: a 13-year longitudinal case after in vitro fertilization treatment
EP01-1059. Venlafaxine in treatment-resistant adolescent depression: a case report
EP01-1060. Feeling more, not less: the effect of psilocybin versus selective serotonin reuptake inhibitors on emotional blunting
EP01-1061. Vitamin D levels and suicidality in patients with major depressive disorder: a systematic review and meta-analysis
EP01-1062. Associations between IL-10, IL-4, IL-6, IL-1B-511, C-reactive protein and brain-derived neurotrophic factor genetic polymorphisms and syndrome-based subtypes of unipolar depression
EP01-1063. Delirious mania with catatonia succesfully treated with electroconvulsive therapy: a case report
EP01-1064. Developing a transdiagnostic core outcome set protocol for perception and understanding of self
EP01-1065. Acute psychosis in a patient with bipolar disorder revealing primary hyperparathyroidism case report
EP01-1066. Reactivation of bereavement following encephalitis in a patient with alzheimer’s disease: a case report
EP01-1068. When hallucinations are not psychiatric: a case of visual- auditory charles bonnet syndrome
EP01-1069. tDCS and working memory training to improve cognitive function in patients with mild Alzheimer’s dementia and mild cognitive impairment
EP01-1071. Unexpected restrictive eating in attention-deficit/hyperactivity disorder: resolution following methylphenidate reintroduction
EP01-1072. Self-reported ADHD traits and academic functioning in first-year university students: preliminary findings from Argentina
EP01-1073. Psychiatric presentation of a child with a COL4A1-related multisystem disorder
EP01-1074. A unique instance of hereditary retinal dystrophy and autism spectrum disorder in a visually impaired child: diagnostic and management challenges
EP01-1076. Social cognition deficits in the J20 mouse model of Alzheimer’s disease
EP01-1077. Sex hormones and ADHD in women: neurobiological mechanisms and clinical implications across reproductive stages
EP01-1078. Significant weight gain following discontinuation of extended-release methylphenidate in an adult with ADHD: a case report
EP01-1079. Atomoxetine response after methylphenidate intolerance in a child with Basilicata-Akhtar syndrome and attention-deficit/hyperactivity disorder
EP01-1080. A rare cause of neurodevelopmental disorder: Luscan–Lumish syndrome associated with de novo SETD2 mutation
EP01-1081. Recurrent severe behavioural dysregulation in a neurodevelopmental disorder associated with 1q21.1 microdeletion: a case report
EP01-1082. Robust response to methylphenidate in a child with Weiss–Kruszka syndrome: the importance of genetic screening in attention-deficit/hyperactivity disorder with dysmorphism
EP01-1084. Autism spectrum disorder and psychosis: symptomatic overlap and diagnostic pitfalls in early intervention services
EP01-1085. Low suicidal ideation and potential sociocultural protective factors among Turkish immigrants in Germany
EP01-1086. Glycyrrhizin improves neuroinflammation and cognitive impairment in Alzheimer’s disease model mice
EP02-2001. Curcumin-loaded liposomes are able to prevent some schizophrenia-related alterations in a maternal immune activation model
EP02-2002. Neuroimaging-based artificial intelligence models for differential diagnosis between Alzheimer’s disease and frontotemporal dementia: a comparative evaluation
EP02-2003. Bipolar disorder with fahr syndrome: a case with hypoparathyroisim and basal ganglia calcifications
EP02-2004. Hydrocephalus mimicking a reversible frontal behavioral syndrome without neurodegenerative pattern
EP02-2005. Normal brain magnetic resonance imaging in anti–N-methyl-D-aspartate receptor encephalitis despite neuropsychiatric presentation
EP02-2006. Frontal dermoid cyst presenting with urinary incontinence
EP02-2007. Altered default mode, salience and sensorimotor network connectivity in left and right temporal lobe epilepsy: a pilot study
EP02-2008. Case report: organic personality disorder and hostility secondary to moyamoya disease
EP02-2009. Impact of parietal and frontal cortical volume on individual differences in visual working memory capacity
EP02-2010. Inherited myopathies and congenital myasthenic syndromes: insights from a turkish cohort
EP02-2011. Psychiatric symptoms in neuro-behcet’s syndrome:a case report of a patient with delusions of jealousy
EP02-2012. Neuroleptic malignant syndrome requiring intensive care unit admission: a case report
EP02-2013. The neurobehavioural spectrum of acute stroke: when vascular lesions mimic psychiatric syndromes
EP02-2014. The multimodal investigation of the assessment of clinician’s subjective experience: the MULTIACSE project
EP02-2015. Rethinking oxytocin in loneliness: a state- and context-dependent predictive processing framework
EP02-2016. Neuropsychiatric and behavioural changes associated with GLP-1 receptor agonist therapy: a systematic review of case-based evidence
EP02-2017. Long-term cognitive sequelae of severe acute respiratory syndrome coronavirus 2 infection: impact of clinical severity
EP02-2018. From emergency intubation to functional status epilepticus: diagnostic and pharmacological challenges in a renal transplant recipient
EP02-2019. Beyond testimonial consent: a negotiated model for epistemic justice and co-expertise in clinical mental health care
EP02-2020. Wartime adaptation profiles in Ukrainian adults: social support, information engagement, sleep recovery and hypervigilance
EP02-2021. Effect of low-intensity transcranial magnetic stimulation on sleep disorders, inflammation levels, and brain-derived neurotrophic factor in patients with depression
EP02-2022. Brain mechanisms and outcomes of electroconvulsive therapy in treatment-resistant depression – a narrative review
EP02-2023. Long-term electroconvulsive therapy exposure and brain aging: a prospective cohort study
EP02-2024. Microstructural changes in prefrontal–cingulate networks following dorsomedial prefrontal cortex-targeted intermittent theta burst stimulation in treatment-resistant depression
EP02-2025. Hypernatraemia associated delirious catatonia responsive to electroconvulsive therapy
EP02-2026. Investigation of the relationship between sex, stress, and internalizing symptoms with resting motor threshold assessed via transcranial magnetic stimulation (TMS)
EP02-2027. Non-invasive brain stimulation to reduce negative symptoms in schizophrenia: a systematic review and network meta-analysis
EP02-2028. Transcranial photobiomodulation as a novel neuromodulation strategy in severe posttraumatic stress disorder: a case report and clinical outcomes
EP02-2029. Multilevel diagnostic framework using EPDS and PDSS for perinatal mental disorders
EP02-2030. Long-term perspectives of parents of extremely preterm-born and/or low-birth-weight infants on support provisions and needs from birth to early adolescence
EP02-2031. Circadian misalignment and sleep disruption i̇n shift work: a bidirectional model of mental health risk
EP02-2032. When illness becomes a bond: dependent personality disorder comorbid with functional neurological disorder and psychotic features
EP02-2033. Non-suicidal self-injury as an emotion regulation strategy in borderline personality disorder: relationship with affect dysregulation severity
EP02-2034. Bipolar disorder, borderline development or trauma-related dysregulation? A complex adolescent case with recurrent hospitalizations
EP02-2035. Association of CES1/SLC6A2 gene polymorphisms with clinical outcomes of methylphenidate treatment in attention-deficit/hyperactivity disorder in a Turkish paediatric cohort
EP02-2036. Pharmacogenomic testing in major depressive disorder: Cytochrome P450 polymorphisms as predictors of antidepressant response and adverse effects
EP02-2037. CYP2D6 metabolizer phenotype is associated with early antidepressant discontinuation in the UK Biobank
EP02-2038. Remyelinating, anti-inflammatory and antioxidant effects of propentofylline in a gliotoxic demyelinating model in rats
EP02-2039. Intranasal ketamine in the management of Treatment-Resistant Depression – a small cohort study from Unidade Local de Saúde de Coimbra
EP02-2040. Enhanced sensitivity to esketamine in elderly treatment-resistant depression: marked response to low-dose intranasal therapy
EP02-2041. Low-dose gabapentin for chronic hiccup and belching-like episodes with functional features in an elderly patient: a case report
EP02-2042. Sertraline-induced lipid storage myopathy mimicking multiple acyl-CoA dehydrogenase deficiency: a case report
EP02-2043. Clozapine and long-acting paliperidone palmitate associated hyperammonaemia: a case report
EP02-2044. From antipsychotic polypharmacy to functional recovery: a case report on rationalization with clozapine and long-acting aripiprazole
EP02-2045. Use of an injection of aripiprazole given once every 2 months (Abilify Asimtufii®): clinical considerations and experiences
EP02-2046. Venlafaxine augmentation in an adolescent with narcolepsy and cataplexy: a case report
EP02-2047. Sustained improvement of refractory sleep disturbance and agitation with low-dose quetiapine in Sanfilippo Syndrome
EP02-2048. Oxcarbazepine-induced hyponatraemia in an elderly psychiatric patient: a case report
EP02-2049. Cardiovascular haemodynamic profile among users of psychotropic medication: a cohort-based matched analysis in the African-PREDICT study
EP02-2050. Early onset acute dystonia and tremor following sertraline treatment in an adolescent with depressive disorder
EP02-2051. Effect of citicoline on cell viability in lipopolysaccharide-stimulated human microglial cells
EP02-2052. Cariprazine–clozapine combination as an augmentation strategy to reduce negative, affective and cognitive symptoms in psychotic disorders
EP02-2053. Diagnostic challenge between anticholinergic toxicity and evolving neuroleptic malignant syndrome during long-acting risperidone treatment
EP02-2054. Metabolic side effects of psychopharmacotherapy - well known, but well considered?
EP02-2055. Social cognition in schizophrenia: associations with clozapine use across theory of mind and emotion recognition
EP02-2056. Before you blame the drug: the importance of excluding benign ethnic neutropenia
EP02-2057. Are 3 days enough? Clinical decompensation following minor delays in long-acting injectable risperidone administration
EP02-2058. Five-year trends in hypnotic drug consumption: a comparative analysis between the Republic of Serbia, Croatia, and Spain (2020-2024)
EP02-2060. Child psychiatrists’ perspectives on speech and language therapy in Türkiye
EP02-2061. Psilocybin-based interventions for depressive symptoms: robustness and variation across meta-analytic specifications
EP02-2062. Yoga for cancer-related fatigue and anxiety in pelvic malignancies: a systematic review and meta-analysis
EP02-2063. Narrative therapy for anorexia nervosa: a case study
EP02-2064. Cognitive analytic therapy in obsessive spectrum, anxiety and depression disorders: a systematic review
EP02-2065. Long-term sustainability of dog-assisted therapy in fetal alcohol spectrum disorder: 12-month follow-up of child and caregiver outcomes
EP02-2066. Eye movement patterns during free visual exploration in schizophrenia: scanpath organization and group differences
EP02-2067. Affective stratification of peripheral inflammatory markers in first-episode psychosis
EP02-2068. Paraphrenia as a psychopathological construct: a case with systematized delusion and depressive symptoms
EP02-2069. Sex-specific neurocognitive patterns in schizophrenia spectrum psychoses: psychometric quantification and neurobiological implications
EP02-2070. Psychotic symptoms as the presenting feature of advanced human immunodeficiency virus infection in a low-prevalence European setting: a case report
EP02-2071. Temporal precision and accuracy in clinically stable patients with schizophrenia: an exploratory study
EP02-2072. Electroconvulsive therapy–associated recurrent transient neuropsychiatric episodes in treatment-resistant schizophrenia: a case report
EP02-2073. Real-world effectiveness, safety and tolerability of aripiprazole 2-month ready-to-use 960 mg: an 18-month follow-up study in outpatients with schizophrenia
EP02-2074. Clozapine + aripiprazole: is this the new duo? - a review and analysis
EP02-2075. Antipsychotic efficacies and side-effects evaluation and head-to-head comparison of xanomeline and KarXT in preclinical rodent models of schizophrenia
EP02-2076. Remission of psychosis in Lambert–Eaton myasthenic syndrome after electroconvulsive therapy
EP02-2077. Overcoming antipsychotic-induced parkinsonism: efficacy of monthly long-acting risperidone in a complex schizophrenia case
EP02-2078. Whole-brain c-Fos mapping reveals distinct activation signatures of reference anti-psychiatric compounds
EP02-2079. Transdermal blonanserin in schizophrenia: a real-world comparison with oral tablets
EP02-2080. Persistent cenesthetic hallucinatory experiences in a chronic refractory pain patient with intrathecal ziconotide exposure: a diagnostic challenge in complex polypharmacy
EP02-2081. Catatonia as the initial presentation of first-episode psychosis: a case report
EP02-2082. Sociodemographic and clinical predictors of response in early psychosis: a focus on gender and migration
EP02-2083. Effects of new synthetic cannabinoid compounds on neuronal viability in schizophrenia subjects-derived olfactory neuroepithelial cell cultures
EP02-2084. Daridorexant for post-stroke sleep disorders comorbid with obstructive sleep apnea: a case report
EP02-2085. Beyond insomnia: diagnostic discordance and pharmacotherapy in a preliminary psychiatric sleep clinic cohort
EP02-2086. The regulation of social behaviour by the medial prefrontal cortical neurons projecting to the medial preoptic area
EP02-2087. Long-term follow-up study of medicinal cannabis in post-traumatic stress disorder: focus on aggressiveness, impulsivity, and suicidality
EP02-2088. Factors influencing on willingness to intervene in bullying among middle school adolescents
EP02-2089. The alpha-2A adrenoceptor agonist guanfacine regulates traumatic stress processing in juvenile zebrafish
EP02-2090. Sexual dysfunction associated with long-acting injectable antipsychotics: a systematic review
EP02-2091. Sex differences in the effects of antipsychotic drugs in adults with acute schizophrenia: an individual-participant-data meta-analysis
EP02-2092. Electroconvulsive therapy for refractory interictal psychosis in focal epilepsy
EP02-2093. Sertraline-induced stevens-johnson syndrome managed successfully with cognitive behavioural therapy: a rare case
FS01.01. In conversation – Putting the mouth back into the body: exploring the reciprocal relationships between oral and mental health
KL01.01. Neural mechanisms of social homeostasis
MS01.01. Depressive symptoms and amyloid pathology
MS02.01. A stratified precision medicine trial targeting α2a-adrenergic receptor agonism as a treatment for the cognitive biotype of depression
MS02.02. Results of the phase 2 OLIVE trial testing the vasopressin 1b antagonist nelivaptan (BH-200) in major depressive disorder
PD02.01. The ECNP AI in mental health network – a european-led coordinated effort for clinical AI implementation
PL01.01. Protein monoaminylation in the brain: novel mechanisms of neural development, plasticity, and disease
PL02.01. How will we get novel medicines in psychiatry? Lessons from schizophrenia
PL04.01. Rethinking women's brain health across the lifespan: the power to change
PL05.01. Advancing mental health in a changing world: social context and biology
PL06.01. Virtual reality in youth mental health: evidence, applications and future directions
PPT-008. Mental health and research leadership: supporting scientists through life transitions
PPT-030. The role of real-world evidence in TRD/MDD decision making
PS01-1001. Blood-brain barrier and neuroimmune alterations induced by methamphetamine: a preclinical study
PS01-1002. Disrupting a cannabinoid-related receptor heterodimer as a newly identified therapeutic approach for cannabis use disorder treatment
PS01-1003. Effect of kappa opioid receptor activation before extinction on reinstatement of cocaine conditioned place preference
PS01-1004. Stress effects on mesolimbic dopamine signalling and alcohol cue reactivity in alcohol use disorder: a PET-MR study
PS01-1005. Deep transcranial magnetic stimulation in cocaine use disorder: the impact on craving and psychopathological burden
PS01-1006. Dopamine D2/D3 receptor partial agonists reduce craving in substance use disorders: a systematic review and meta-analysis
PS01-1007. Computational profiling of reinforcement learning under dopaminergic modulation in stimulant use disorder and obsessive-compulsive disorder
PS01-1008. Methadone detoxification using buprenorphine microinduction (Bernese method): a case report
PS01-1009. Nitrous oxide dependence, neurotoxicity and a coordinated municipal response while using municipal waste as surveillance tool: a quasi-experimental implementation study
PS01-1010. Prevalence of traumatic life events and post-traumatic stress disorder among patients admitted to an addiction day hospital
PS01-1011. Association between reduced hippocampal neuronal integrity and mtDNA D-loop methylation in a chronic unpredictable mild stress rat model
PS01-1012. Gestational stress disrupts maternal behaviour through neuroendocrine, immune and oxidative dysregulation
PS01-1013. Environmental conditions modulate stress-induced behavioural and immuno-metabolic outcomes through sex-dependent effects
PS01-1014. Early life stress alters hypothalamic–peripheral metabolic signaling linking psychiatric and metabolic vulnerability
PS01-1015. Modulation of CSF flow and tracer brain influx in pigs in vivo using SPECT
PS01-1016. Assessment of lumateperone partial agonist activity at presynaptic dopamine D2 autoreceptors: reversal of haloperidol-induced tyrosine hydroxylase phosphorylation in mouse striatum
PS01-1017. Dose-dependent neuroprotective effects of liraglutide in penicillin-induced epileptic neurotoxicity in rats
PS01-1018. Repurposing approved drugs for streptozotocin-induced central nervous system impairments
PS01-1019. LB-102 effect on dopamine D2 autoreceptors: Results from a preclinical study evaluating dopamine efflux in rat nucleus accumbens using microdialysis
PS01-1020. Spectral EEG distributions in generalized anxiety disorder using a large hospital-based clinical EEG database
PS01-1021. Residual symptoms of selective mutism in adolescence: associations with perfectionism and psychopathology
PS01-1022. Inhibitory control dysfunctions in anxiety: reactive vs. proactive mechanisms
PS01-1023. Differential changes in autonomic and somatomotor startle responses during psychotherapy in panic disorder
PS01-1024. Moderators of placebo effect in Generalized Anxiety Disorder (GAD) trials: a meta-regression analysis
PS01-1025. Intranasal esketamine in treatment-resistant depression: longitudinal changes in anxiety and correlations with depressive symptoms, functioning, and suicidality in real-world practice
PS01-1026. Targeting γ1-containing GABA-A receptors spares γ2-benzodiazepine mediated neurophysiological impairments in human volunteers
PS01-1027. The relationship between metacognitive beliefs, emotion recognition, interpersonal emotion regulation, and attachment styles in patients with anxiety disorders
PS01-1028. Psychometric properties of a treatment monitoring instrument for social anxiety disorder: The Turkish version of the Social Attitudes Questionnaire (SAQ)
PS01-1029. Real-world outcomes of esketamine in major depressive disorder with comorbid anxiety or trauma and stress-related disorders (ELLIPSE Study)
PS01-1030. A small open language model captures linguistic signatures of mental health conditions in social media posts
PS01-1031. AI-driven speech analysis for screening common psychiatric symptoms and investigating their impact on occupational performance in non-clinical hospital staff
PS01-1032. Performance of an MRI-based psychosis risk score varies by symptom burden and brain maturation
PS01-1033. Baseline inflammation predicts symptomatic response to interleukin-2 in unipolar and bipolar depression
PS01-1034. Hearing anhedonia: quantifying vocal digital phenotypes across psychiatric disorders
PS01-1035. Spontaneous sentence elaboration as a projective vocal probe for sub-clinical distress: a comparison with autobiographical recall tasks
PS01-1036. Predicting Parkinson’s psychosis: a machine learning and structural imaging approach
PS01-1037. Aging-related long non-coding RNA expression in bipolar disorder: effects of familial liability and childhood trauma
PS01-1038. Peripheral inflammation in bipolar disorder: impact of childhood trauma and metabolic dysregulation
PS01-1039. The role of the glutamate system in major depressive disorder with comorbid anxiety: A comprehensive 7 tesla multimodal neuroimaging study
PS01-1040. Fibromyalgia in the UK Biobank: a confirmatory study on the relationship between multimodal neuroimaging and nociplastic pain
PS01-1041. Investigating emotional experience and thought disorganization across treatment-resistant and responsive schizophrenia during emotional stimulation under electroencephalographic recording
PS01-1042. GenoDisc: an open-source functional genomics pipeline for drug repurposing and biomarker discovery applied to amyotrophic lateral sclerosis
PS01-1043. Longitudinal trajectory of c-reactive protein and its association with troponin levels during clozapine titration in treatment-resistant schizophrenia
PS01-1044. A normative reference framework for resting-state network connectivity in psychiatry
PS01-1045. Integrative plasma proteomics and genomics identify causal drivers and drug targets for major psychiatric conditions
PS01-1046. Plasma levels of inflammatory, endothelial, metabolic and glial markers in first-episode psychosis: A cross-sectional study
PS01-1047. Multimodal CSF immune profiling in first-episode psychosis reveals blood–CSF barrier dysfunction and synaptic autoantibody enrichment
PS01-1048. Increased mitochondrial DNA d-loop methylation in major depressive disorder
PS01-1049. Mitochondrial alterations in adult ADHD: insights from hiPSC-derived neurovascular models of PARK2 copy number variants
PS01-1050. Relationship between emotional disorders, problematic smartphone use, and smartphone addiction in the medical academic environment
PS01-1052. Mobile app-based detection and symptom trajectories of postpartum depression using ecological momentary assessment: a prospective cohort validation study
PS01-1053. Behavioural and cognitive correlates of smartphone overdependence in preschoolers with and without developmental disabilities
PS01-1054. Spontaneous emotional self-reports in digital mental health platforms: behavioural signatures and implications for affective regulation
PS01-1055. Epigenetic dosage establishes individual vulnerability states in reward circuitry
PS01-1056. Early intervention in anorexia nervosa: a case series of three adolescents
PS01-1057. Altered resting-state network connectivity and its clinical correlates in anorexia nervosa: an independent component analysis study
PS01-1058. A five-year persistence of antidepressant polypharmacy and associated pharmacological risk in a community cohort
PS01-1059. Antipsychotic and ADHD medication use patterns among young children in South Korea
PS01-1060. Trends in outpatient prescribing of long-acting injectable antipsychotics among patients diagnosed with schizophrenia in Germany (2012–2021)
PS01-1061. Antipsychotic medications and the risk of major adverse cardiovascular events in patients with schizophrenia
PS01-1062. Public perceptions of psychedelics: results from a survey in the general Norwegian population
PS01-1063. Striatal serotonin 4 receptor binding and female sexual desire: cross sectional positron emission tomography results
PS01-1064. Cognitive flexibility and hormonal contraceptive use: a cross-sectional study in healthy women
PS01-1065. Implications for antidepressant treatment and novel therapeutic strategies after traumatic brain injury: preliminary results of the CAROLINA-MTC study
PS01-1066. Gut microbiome changes after synbiotic treatment in adults with attention-deficit/hyperactivity disorder and/or borderline personality disorder
PS01-1067. Antibiotic perturbation of the gut microbiota in zebrafish larvae reveals a microbiota-gut-brain axis signalling pathway influencing behaviour and neurobiology
PS01-1068. Anti-Ma2 encephalitis presenting as treatment-resistant bipolar disorder: a case report with diagnostic and immunotherapeutic implications
PS01-1069. Altered immune–autonomic and neurovisceral coupling in late-onset depression: a multimodal dimensional study combining gene expression, HRV, and fMRI
PS01-1070. Metabolic dysregulation and neuropsychiatric burden in Long-COVID: linking fatigue, depression, and cerebral energy metabolism
PS01-1071. First-episode mania with catatonic features as the heralding presentation of anti-NMDA receptor encephalitis: a case report
PS01-1072. Prospective study of clinical predictors of outcome and response to treatment in obsessive-compulsive disorder: Barcelona child and adolescent OCD cohort
PS01-1073. Avoidant/restrictive food intake disorder symptom profiles and association with cognitive flexibility in children and adolescents with obsessive-compulsive disorder
PS01-1074. Clinical and cognitive outcomes following gamma knife capsulotomy in treatment-resistant obsessive–compulsive disorder
PS01-1075. Can we model anxio-depressive states through auditory-driven escape behaviour in mice
PS01-1076. Restoring emotional stability through Neurofeedback and AI for transformative empowerment
PS01-1077. Anxiety severity, childhood trauma and clinical outcomes in euthymic patients with mood disorders
PS01-1078. Sex differences in prodromal features preceding bipolar disorder: evidence from electronic health records integrating natural language processing
PS01-1079. Circulating miRNA signatures following cognitive remediation in depressive disorder: Insights from plasma and neuron-derived extracellular vesicles
PS01-1080. Peripheral immune cell phenotypes associated with depression risk, diagnosis and remission in adolescents
PS01-1081. Allostatic load and pain-depression comorbidity: a mediation analysis of bilirubin
PS01-1082. Towards an integrated staging model of bipolar disorder: preliminary results from a multicentre study
PS01-1083. Differential diagnosis of melancholic depression and bipolar disorder using machine learning–assisted proximity extension assay-based plasma proteomic analysis
PS01-1084. Mitochondrial transfer mechanisms in mood disorders: A cellular and clinical investigation of MIRO and TRAK expression
PS01-1085. Is it possible to predict inpatient suicide in psychiatric hospitals?
PS01-1086. Perimenopause is associated with lower cognitive performance and higher depressive symptoms compared to postmenopause
PS01-1087. Menstrual cycle regularity in women with bipolar disorders: associations with premenstrual disturbances, hormonal contraceptives and course of illness
PS01-1088. From peripheral inflammation to CNS injury: composite indices capture neuropsychiatric burden in stable autoimmune disease
PS01-1089. Do dynamic features of resting-state fMRI functional connectivity reflect current depressive symptom severity in major depressive disorder?
PS01-1090. Left hippocampal connectivity links Toxoplasma gondii seropositivity to depression severity in hospitalised major depression
PS01-1091. White matter microstructure in the postpartum period and perinatal depressive symptoms: a TBSS study
PS01-1092. Distributed brain network hypoconnectivity linked to suicide attempt history and childhood sexual abuse in depression
PS01-1093. Longitudinal endocrinological correlates of white matter integrity loss during the postpartum period
PS01-1094. Network-based plasticity across neural and symptom levels reflects the capacity for change in depression
PS01-1095. Pre-treatment fMRI working memory activation predicts functional remediation outcomes in older adults with bipolar disorder
PS01-1096. Effects of short-term estrogen intervention on cognitive function in women at high risk of postpartum depression
PS01-1097. Kynurenine pathway metabolites and grey matter volumes in peripartum depression: a voxel-based-morphometry study
PS01-1098. Interim analysis of HIPOCRAT-ESK study: depression severity and functional changes after 5-month esketamine nasal spray treatment in Spanish real-world population
PS01-1099. Metabolic profile of adjunctive lumateperone 42 mg in major depressive disorder: A pooled analysis of 2 randomized, placebo-controlled trials
PS01-1100. Lumateperone 42 mg in patients with major depressive disorder: analysis of remission in short- and long-term trials
PS01-1101. Lumateperone 42 mg in major depressive disorder: demographic and clinical subgroups efficacy analysis in a phase 3 randomized placebo-controlled trial
PS01-1102. Linking Montgomery-Åsberg Depression Rating Scale and patient health questionnaire total scores: evidence from adjunctive lumateperone trial data
PS01-1103. Efficacy of adjunctive lumateperone 42 mg treatment across a broad range of depression symptoms in patients with major depressive disorder
PS01-1104. Real-world evolution of intranasal esketamine use in Gipuzkoa (Spain) across 2023–2025 cohorts
PS01-1105. Cardiometabolic risk after antidepressant and antipsychotic treatment in major depressive disorder: evidence from German health claims data
PS01-1106. Targeting the reward circuitry: low-dose methylphenidate for motivational anhedonia in pediatric depression
PS01-1107. Within-person changes in positive bias predict subsequent depressive symptoms: a longitudinal mixed-effects study in primary care
PS01-1108. Identifying stable cognitive clusters in a cohort of patients with major depressive disorder: A BrainDrugs-Depression study
PS01-1109. Magnitude and trial methodology moderators of treatment response variance in major depressive disorder: a pooled analysis across 16 clinical studies
PS01-1111. Indirect pathways linking hypertension and depression: a multiple mediation analysis using national population data
PS01-1112. Beyond impulsivity: planning in suicide reattempts at one-year follow-up in the SURVIVE cohort
PS01-1113. Antidepressant discontinuation during screening does not confound efficacy in treatment-resistant depression: a Phase 2b evaluation of intranasal mebufotenin benzoate (BPL-003)
PS01-1114. Specific association of SLC6A4, but not BDNF, methylation with uncinate fasciculus integrity in drug-naïve major depressive disorder
PS01-1115. Effectiveness of acceptance and commitment therapy for suicidal ideation: a systematic review and meta-analysis
PS01-1116. Exploring novel treatment options for patients with psychiatric disorders: brenipatide clinical trials
PS01-1117. Metabolic profiles of participants with major depressive disorder with insomnia symptoms: phase-3 trial of seltorexant versus quetiapine-XR as adjunctive therapy
PS01-1118. Associations between emotion dysregulation and multiple sleep domains in bipolar disorder: differential patterns across sleep quality, insomnia and daytime sleepiness
PS01-1119. Impact of seltorexant on cognitive performance of adults with major depressive disorder with insomnia symptoms
PS01-1120. Kynurenine pathway dysregulation in peri- and postpartum depression: a systematic review
PS01-1121. Trauma burden and personality as moderators of esketamine response in treatment-resistant depression: interim analysis of a naturalistic registry
PS01-1123. DKK2 secretion by activated microglia in Alzheimer’s disease contributes to blood-brain barrier dysfunction
PS01-1124. Sacsin deficiency drives early alterations in glial intermediate filament and astroglial reactivity in zebrafish
PS01-1125. Smartphone motor testing detects acute levodopa responsiveness in Parkinson’s disease
PS01-1126. The association between haemoglobin level and risk of developing dementia
PS01-1127. Neural correlates of apathy : a transdiagnostic systematic review
PS01-1128. At the crossroads of neurology and psychiatry: an Alzheimer-related corticobasal syndrome with seizure
PS01-1129. From nihilistic delusions to neurodegeneration: Cotard’s syndrome as a prodromal manifestation of behavioural variant frontotemporal dementia: a case report
PS01-1130. Neuropsychiatric presentation of genetically confirmed juvenile Niemann–Pick type C in two siblings
PS01-1131. Neuropsychiatric red flags and ethical dilemmas in rapidly progressive cognitive decline: a Creutzfeldt-Jakob disease case report
PS01-1132. Premorbid psychiatric history and neuropsychiatric symptoms in dementia subtypes
PS01-1133. Trends in adult attention deficit hyperactivity disorder and psychiatric comorbidities over time
PS01-1134. Gender bias in diagnosis and treatment planning of adult ADHD: a randomised vignette study among Turkish psychiatrists
PS01-1135. Beyond core symptoms: emotion dysregulation and depression as sequential mediators of quality of life in adult women with attention-deficit/hyperactivity disorder
PS01-1136. Reduced nucleus accumbens serotonin 1B receptor availability and its association with synaptic density in adults with autism spectrum disorder
PS01-1137. Psychopathology risk reshapes the hierarchical socioeconomic impact on personalized functional network topography in children
PS01-1138. Different sex profiles in preschool children screened for autism spectrum disorder in primary care
PS01-1139. Beyond inattention: eating attitudes, metabolic parameters and their clinical correlates in adults with ADHD — a case control study
PS01-1140. A child with autism spectrum disorder and Alagille Syndrome: dual molecular diagnosis with de novo FOXP1 and NOTCH2 variants
PS01-1141. Sleep quality mediates the association between chronotype and emotional dysregulation in adults with attention deficit hyperactivity disorder
PS01-1142. The association between childhood maltreatment and conduct disorder: a systematic review and three level random effects meta-analysis
PS01-1143. Neonatal limited bedding and nesting experience drives sex-specific panic-like defensive behaviours and microglial phenotypic alterations in mice
PS01-1144. Can locus coeruleus structural and functional changes serve as a biomarker for Alzheimer’s disease: a systematic review and meta-analysis
PS01-1145. Mental imagery in anxiety and depressive disorders: neuroimaging correlates for psychotherapy, neurofeedback, and neuromodulation
PS01-1146. A study on the brain activation related to cognitive empathy and emotional empathy in adolescent ADHD patients
PS01-1147. Effects of chronic oxytocin administration on white matter microstructure in autistic adults: a pharmaco-neuroimaging DTI study
PS01-1148. MIND-based morphometric similarity networks for bipolar disorder classification via graph neural networks
PS01-1149. Towards neuroimaging-based biotypes in the neuromodulation of depression
PS01-1150. Breathwork-induced changes in cerebral blood flow, functional connectivity and altered states of consciousness: similarities and differences with psychedelic research
PS01-1151. Polygenic influences on brain structure in youth across the psychosis-spectrum
PS01-1152. Higher blood-brain barrier leakage in schizophrenia-spectrum disorders: a replication study using dynamic contrast-enhanced magnetic resonance imaging
PS01-1153. SV2A-PET reveals transcriptomic excitatory-inhibitory imbalance in schizophrenia
PS01-1154. Decoding the links between psychosis and autism: neuroanatomical markers of autistic-like symptoms in first-episode psychosis
PS01-1155. Biobehavioural correlates of physical and mental health-related quality of life in relapsing- remitting multiple sclerosis
PS01-1156. Effects of LB-102 on cognitive performance in patients with schizophrenia: Post hoc analyses from the phase 2 randomised NOVA-1 trial
PS01-1157. Human iPSC-derived guided cortical organoids as a platform to study C4A-associated mechanisms in schizophrenia
PS01-1158. Data-driven EEG subtyping of adolescents with non-suicidal self-injury: a machine-learning approach
PS01-1159. Closed-loop respiratory-gated transcutaneous auricular vagus nerve stimulation reduces beta power in healthy volunteers
PS01-1160. Thujone-rich essential oil from Aloysia deserticola (Rica-rica) decreases hippocampal inhibitory synaptic transmission in mice
PS01-1161. Psilocybin treatment and cognitive outcomes in treatment-resistant depression: results from a randomized controlled trial
PS01-1162. Neuropsychological predictors of cognitive reserve in Parkinson's disease and cognitive impairment
PS01-1163. Long-term cognitive sequelae in COVID-19 patients: Differences according to acute-phase C-reactive protein levels
PS01-1164. How to induce stronger placebo analgesia: a refined methodological proposal
PS01-1165. Guiding principles for youth participation in biological mental health research: The CELEBRATE Consensus Framework
PS01-1166. Insulin-like growth factor-dynamics during electroconvulsive therapy: a neuropsychopharmacological signature?
PS01-1167. Testing the mind when treating the brain: a clinical audit of cognitive assessments in electroconvulsive therapy
PS01-1168. Venlafaxine-associated catatonia and elevated seizure threshold during electroconvulsive therapy
PS01-1169. Electrophysiological neural network reorganisation in patients with depression undergoing electroconvulsive therapy is linked to treatment response
PS01-1170. A psychosis-specific prediction model for violent reoffending following discharge from forensic psychiatric care – FoVOx-P
PS01-1171. Data-driven stratification of perinatal depression risk: integrating metabolic and psychosocial factors to disentangle heterogeneity in perinatal depression
PS01-1172. Co-occurrence of mental health and substance use problems in the perinatal period: prevalence and associated factors
PS01-1173. Peripheral amino acid neurotransmitter dynamics during pregnancy and its implications on gestational diabetes mellitus and depression
PS01-1174. Beyond monoamines: neurosteroid modulation of extrasynaptic GABA-A receptors by zuranolone and brexanolone in postpartum depression
PS01-1175. Targeting affective cognition during pregnancy to prevent postpartum depression: a randomized controlled trial with parity-specific effects
PS01-1177. Diagnostic performance and threshold-dependent accuracy of the PTSD checklist for DSM-5 in perinatal post-traumatic stress disorder
PS01-1178. The relationship between borderline personality disorder, suicidal ideation, impulsivity, and the Castelli index
PS01-1179. Impact of actionable genotypes on antidepressant treatment discontinuation in inpatients with depressive disorders: a prospective observational study
PS01-1180. DT-101, an α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor positive allosteric modulator, gave target-relevant magnetoencephalographic responses in healthy adults in first in human trial
PS01-1181. A retrospective pilot analysis of patients with persistent neuropsychiatric symptoms in post-acute infectious syndromes treated with (es)ketamine
PS01-1182. A meta-analysis of two phase 3 randomised placebo-controlled trials of zuranolone for the treatment of postpartum depression
PS01-1183. Zuranolone efficacy and safety by baseline symptom severity on the Montgomery-Asberg Depression Rating Scale: post-hoc analysis of SKYLARK and ROBIN
PS01-1184. Regulatory approvals and reimbursement pathways for psychiatric treatments in the United States and Europe: a targeted literature review
PS01-1185. Brenipatide, a glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 receptor agonist: clinical data supporting dose selection for neuropsychiatric and immunological indications
PS01-1186. The PRIME-D trial: improving recovery in depression through pro-cognitive pharmacological enhancement of cognitive behavioral therapy
PS01-1187. Clarithromycin-induced mania with psychotic features: the diagnostic challenge of differentiating primary psychiatric disorders from organic neuropsychiatric syndromes
PS01-1188. Affective and metabolic effects of 2,4-dinitrophenol in ovariectomised rats fed a high-fat diet
PS01-1189. Long term toxicity of lithium treatment – a longitudinal population based study
PS01-1190. Trazodone serum levels are not significantly affected by factors such as age, gender, body mass index or smoking: pilot results
PS01-1191. Psychometabolic outcomes of incretin-based therapy in a real-world cross-diagnostic psychiatric cohort
PS01-1193. Intravenous Citalopram and acute cardiac repolarisation: a pilot electrocardiographic monitoring study
PS01-1195. Risperidone-ISM in early-phase schizophrenia: effectiveness and functioning in acutely exacerbated participants from the RESHAPE study
PS01-1196. Neuropsychiatric characterization and psychopharmacological profiles of type 2 diabetes phenotypes: a cross-sectional cluster analysis
PS01-1197. Interleukin-17 and T-helper 17 cells in treatment-resistant depression: from neuroinflammatory mechanisms to precision immunomodulatory strategies: a mini-review
PS01-1198. BDNF DNA methylation as a potential predictive biomarker of treatment response in major depressive disorder: a mini-systematic review
PS01-1199. Beyond trial-and-error: AI-guided antidepressant selection using integrated genetic and clinical data in major depressive disorder
PS01-1200. Microbiome depletion prevents psilocybin’s antidepressantlike effects in adolescent rats of both sexes
PS01-1201. Real-world evidence suggests rethinking continuation criteria for ketamine in treatment-resistant depression
PS01-1202. Boundary conditions of psychedelic plasticity: Empathy and mentalizing networks remain stable after DMT and harmine in experienced meditators
PS01-1203. Single-dose ayahuasca for depressive and anxiety symptoms associated with cancer diagnosis: a single-blind feasibility proof-of-concept trial
PS01-1204. When the background matters: reference lists selection impacts brain genome-wide association studies and exome enrichment analyses
PS01-1205. Divergent genetic architecture of depression and suicidal behavior: insights from polygenic risk scores
PS01-1206. CLOCK and PER3 gene interactions and heterozygote advantage influence eating behaviour in bipolar disorder
PS01-1207. Replication and transdiagnostic validation of genetic risk profiles in schizophrenia
PS01-1208. The exposome score for schizophrenia in a first-episode psychosis sample: predictive performance and sample-specific recalibration
PS01-1209. Analysis and comparison of cerebrospinal fluid and serum proteomics in schizophrenia, multiple sclerosis, and clinical controls
PS01-1210. Peripheral immune inflammation in schizophrenia: group-level elevation with limited diagnostic separation – a case-control study
PS01-1211. Corticosteroid-induced delusional infestation: a case report
PS01-1212. Twenty-year trajectories of individual negative symptoms following first hospitalisation for schizophrenia
PS01-1213. Phenotyping of atypical psychiatric inpatients screened for autoimmune encephalitis
PS01-1214. Effort-based decision-making in familial high-risk individuals for bipolar disorder and psychosis: a computational modeling study
PS01-1215. Early-onset psychosis in a child with an intragenic ANKRD17 duplication: A case report
PS01-1216. SP4 dosage-dependent disruption of neuronal maturation and excitatory/inhibitory balance in human iPSC-derived forebrain neurons
PS01-1217. Neuropsychiatric manifestations due to metabolic and structural dysfunction: two cases of hyperostosis frontalis interna
PS01-1218. Pre-treatment brain structural associations with temporal evolution of extrapyramidal symptoms over 24-month of antipsychotic treatment in first-episode schizophrenia spectrum disorders
PS01-1219. Cognitive insight in schizophrenia reflects dissociable temporal and agency-related mechanisms
PS01-1220. Long-term metabolic and cardiovascular safety and tolerability with xanomeline and trospium chloride: pooled results from EMERGENT-4 and EMERGENT-5
PS01-1221. Occurrence of urinary retention-related adverse events with xanomeline and trospium chloride: results from the 52-week, open-label EMERGENT-5 trial
PS01-1222. Efficacy and safety of xanomeline/trospium chloride during transition from atypical antipsychotics in participants with stable schizophrenia symptoms in EMERGENT-5
PS01-1223. Regulation of metabotropic glutamate receptors 4 and 7 by microRNAs in the dorsolateral prefrontal cortex of subjects with schizophrenia
PS01-1224. Comparative analysis of the diagnostic performance of clinical high risk for psychosis (CHR-P) instruments based on reported data
PS01-1225. CYP2D6 metaboliser status impact on xanomeline and trospium chloride efficacy and tolerability in adults with schizophrenia: a post hoc analysis
PS01-1226. Phase 3 clinical development program of LB-102 in schizophrenia: A double-blind placebo-controlled trial (NOVA-2) and an open-label extension study (NOVA-3)
PS01-1227. HS-10380 in patients with schizophrenia: a phase 2b randomised placebo– and active-controlled trial
PS01-1228. Exposure–response relationship of once-monthly subcutaneous olanzapine (TV-44749) for clinical and functional outcomes in schizophrenia
PS01-1229. Functional remission following early initiation of long-acting injectable paliperidone in a young professional athlete with schizophrenia: a case report
PS01-1230. Factors predicting symptom stability without antipsychotic treatment in schizophrenia: analysis of 557 patients on placebo for at least 6 months
PS01-1231. Temporal patterns of clozapine utilization and initiation timing in schizophrenia: a nationwide retrospective cohort study in south korea, 2010–2021
PS01-1232. Three-level, resistance-informed clinical staging model for schizophrenia: a Delphi-based expert consensus
PS01-1233. Relationships between alexithymia, metacognitive beliefs, and severity of psychotic symptoms in schizophrenia patients
PS01-1234. Recurrent psychosis associated with Panax notoginseng supplement use: a case report
PS01-1235. Insight in schizophrenia shows a genetic signature: evidence from SOX2-OT and PTPRZ1 polymorphisms
PS01-1236. Associations between GABA and glutamate levels with pain presence and depressive symptoms in obstructive sleep apnea
PS01-1237. Chronotherapy in a sighted woman with non-24-hour sleep-wake rhythm disorder: a case study
PS01-1238. Depressive and attentional symptoms in narcolepsy: findings from patients, first-degree relatives, and controls
PS01-1239. Daridorexant in patients with insomnia and psychiatric comorbidity: long-term real-world clinical experience
PS01-1240. Impact of sleep latency and efficiency on metabolic syndrome in schizophrenic patients
PS01-1241. Metastability as a candidate biomarker in psychotic disorders: a narrative review
PS01-1242. Depression and serum cholesterol are the strongest correlates of suicidal ideation in combat-related post-traumatic stress disorder
PS01-1243. Psychosocial burden and unmet needs among caregivers of children with pediatric gliomas: a systematic review
PS01-1244. Multi-context linguistic analysis as an objective diagnostic adjunct for PTSD in earthquake survivors
PS01-1245. Caregiving responsibilities for children with neuropsychiatric disorders or other long-term illnesses are associated with exhaustion disorder
PS01-1246. Two distinct pathways from childhood trauma to functional impairment in adults with attention-deficit/hyperactivity disorder
PS01-1247. Intra-semester dynamics of academic stress, perceived stress, academic engagement and sleep composition in university students: preliminary findings
PS01-1248. Exploring changes in cognitive, clinical, biological and digital measures after 8 weeks dosing MT1988 in participants at clinical-high-risk for psychosis
PS01-1249. MT1980: translating anti-inflammatory and metabolic mechanisms into new treatment opportunities for schizophrenia
PS01-1250. Efficacy and safety of long-acting aripiprazole 960 mg: preliminary findings from a real-world longitudinal study
PS01-1251. Intranasal esketamine in treatment-resistant depression with and without comorbid borderline personality disorder: a multicenter real-world longitudinal study
PS01-1252. Computational modelling reveals long-lasting decision-making impairment in patients with cocaine use disorder
PS01-1253. Therapeutic potential of exercise in post-traumatic stress disorder and underlying mechanisms: living systematic review of studies with ongoing evidence surveillance
PS01-1254. Anticonvulsant activity and toxicity studies of hydroethanolic extract of pseudospondias microcarpa bark in zebrafish models
PS01-1255. N,N-Dimethyltryptamine effects on fear memory reconsolidation depend on neuronal sigma-1 receptors
PS01-1256. Local capacity meets global collaboration: Neuroscience Capacity Accelerator for Mental Health (NCAMH)
PS01-1257. Religion and mental health seeking behaviors in war-torn zones of the Democratic Republic of the Congo
PS01-1258. Behavioral characterization of alprazolam withdrawal in female Wistar rats: social interaction and exploratory activity
PS01-1259. Early detection of psychosis with speech-language analysis using speech-to-text technology and AI in Jakarta Indonesia
PS02-2001. The role of progesterone and related neurosteroids in alcohol use and addiction
PS02-2002. Semaglutide demonstrated differentiated efficacies in preclinical models of alcohol and substance use disorders in rats
PS02-2003. Longitudinal associations between stress, craving, and alcohol use in individuals with alcohol use disorder, investigated using fMRI and EMA
PS02-2004. The effects of cue-induced craving on brain oscillations in alcohol use disorder patients: an electroencephalography study
PS02-2005. Early onset of psychoactive substance use and family factors as risk factors for juvenile delinquency in person experiencing opiate addiction
PS02-2006. MRI-guided continuous theta burst stimulation to reduce craving induced by virtual reality cue exposure in alcohol use disorder
PS02-2007. Pharmacotherapy response across ethanol craving, seeking, and consumption depends on sex and baseline phenotype in alcohol-preferring rats
PS02-2008. Exploring novel treatment options for patients with substance use disorders: brenipatide clinical trials
PS02-2009. Cannabidiol as an adjunct strategy in opioid-use disorder: dissociable effects on physical dependence, psychological effects of withdrawal and drug-seeking behaviour
PS02-2010. Abuse liability of isopropylphenidate via modulation of D1 receptor signalling pathway
PS02-2011. Touchscreen-based assessment of cognitive flexibility and motivation in mice lacking beta2 nicotinic acetylcholine receptors in cholinergic neurons
PS02-2012. Caesarean section birth Is associated with sex-dependent alterations in prefrontal cortex glial development at Wweaning
PS02-2013. Agmatine improves methotrexate-induced neurotoxicity and spatial memory impairment in rats
PS02-2014. Dissociable effects of PINK1 and chronic stress on neuronal number and microglial morphology: implications for non-motor symptoms in parkinson’s disease
PS02-2015. Investigation of the role of agmatine and PI3K/Akt/mTOR signaling pathway in experimental model of autism spectrum disorder
PS02-2016. Effects of olanzapine on glucose metabolism in Negr1-deficient mice: sex-specific differences
PS02-2017. Chronic treatment with the mGluR2 positive allosteric modulator JNJ-46356479 attenuates apoptosis-related alterations in adulthood in a postnatal-ketamine model of schizophrenia
PS02-2018. Maintained JNJ-46356479 treatment, a positive allosteric modulator of mGluR2, improved induced cognitive deficits in a schizophrenia postnatally ketamine-exposed mouse model
PS02-2019. The role of ADAMTS2 in schizophrenia: validation in a novel transgenic mouse model
PS02-2020. Comparative analysis of sleep architecture and circadian rhythms in senescence-accelerated mouse (SAM) P8 and R1 strains
PS02-2021. Letting behaviour speak: how long-term, continuous home-cage observation and deep learning capture stress dynamics
PS02-2022. The social fear conditioning-social buffering paradigm: Attenuation of social fear by social buffering is associated with specific gene expression patterns
PS02-2023. Anaesthesia with ketamine or propofol on the antidepressant-like efficacy and cognitive outcome induced by electroconvulsive stimulation in adolescent rats
PS02-2024. Association between anxiety symptoms, obesity, and the perception of obesity in South Korea
PS02-2025. Temporal misalignment as a transdiagnostic marker of instability in anxiety-related deterioration
PS02-2026. Investigation of the effects of disease process and parent-child disease perception on quality of life in childhood chronic rheumatic diseases
PS02-2027. To approach or avoid? The role of risk and ambiguity in threat–reward decisions
PS02-2028. Korean guidelines for the treatment of generalised anxiety disorder: strategies for insufficient treatment response and comorbidities
PS02-2029. GlyphAgo demonstrated 6.8-fold bioavailability and 10-fold reduced variability versus unmodified agomelatine at doses projected to mitigate liver exposure in humans
PS02-2030. The influence of oxytocin on psycho-emotional behavior and social interaction in early postnatal immobilized male rats
PS02-2031. Pharmacological characterisation of a novel α2/3 GABAA receptor selective positive allosteric modulator
PS02-2032. Anxiety sensitivity in obsessive-compulsive disorder: a case-control study
PS02-2033. Reliability and accuracy of artificial intelligence–based voice analysis for screening depressive symptoms: a systematic review of diagnostic performance
PS02-2034. Interpretable hierarchical RNNs for rs-fMRI: promise and limits of individualised brain dynamics
PS02-2035. Automated linguistic examination across stages of psychosis
PS02-2036. Regional inequities in AI models for psychiatric diagnosis
PS02-2037. Integrating transcriptome and metabolome data for treatment outcome prediction in depression through multi-omics factor analysis
PS02-2038. Adaptive multimodal fusion of behavioural signals for objective mental health assessment
PS02-2039. Artificial intelligence in pharmacovigilance: advances in adverse event detection, signal management, and regulatory reporting
PS02-2040. Computational analysis of speech acoustics in first-episode bipolar disorder and psychosis
PS02-2041. Elevated homocysteine levels as a predictor of stress-associated anxiety and depressive disorders in war-affected Ukrainian adults
PS02-2043. Divergent immunometabolic signatures across adult males and females with major depressive disorder revealed by multi-omics integration
PS02-2044. Epigenetic signatures of childhood trauma in females: a cross-stage study across adolescence and pregnancy
PS02-2045. Proteomic signatures of bipolar disorders
PS02-2046. Stringent cerebrospinal fluid amyloid stratification reveals heterogeneous cerebrospinal fluid and limited plasma phosphorylated tau separation in preclinical Alzheimer’s disease
PS02-2047. Molecular biomarkers associated with cognitive gains from virtual reality rehabilitation in patients with schizophrenia and bipolar disorder
PS02-2048. Use of biomarkers in neuropsychiatric clinical trials: a landscape analysis
PS02-2049. Biomarkers of aging capture cognitive and immuno-metabolic signatures of childhood adversity across data modalities
PS02-2050. A multi-axis blood-based biomarker framework for domain-specific clinical profiling in schizophrenia
PS02-2051. The blood-brain barrier influx-efflux balance drives variability in citalopram brain pharmacokinetics
PS02-2052. Paroxetine-associated weight gain: role of the 5-HT2C receptor
PS02-2053. Identification of DNA methylation-dependent functional regulatory elements in developing brain cells using massively parallel reporter assay
PS02-2054. The clinical blind spot: artificial intelligence risk awareness and clinical preparedness among child and adolescent psychiatrists
PS02-2055. Asking a chatbot for help as psychiatric symptoms escalate: a longitudinal safety evaluation of widely accessible conversational systems
PS02-2056. Social connectedness as a predictor of suicidal outcomes in psychiatric outpatients: a 12-month prospective EMA study
PS02-2057. Remote monitoring of depression and bipolar disorder: preliminary data on implementation from the EC-102 multicenter randomised controlled trial
PS02-2058. Wearable-based statistical modelling for predicting depressive symptom worsening
PS02-2059. Evening chronotype as a predictor of eating disorders: a systematic review and meta-analysis
PS02-2060. Protective and sustaining mechanisms in anorexia nervosa: a latent profile analysis
PS02-2061. Intravenously administered psilocin for binge eating disorder: Preliminary safety and psychedelic intensity from a Phase 1 open-label trial
PS02-2062. Temporal mapping of electroencephalographic dynamics during intravenous psilocin administration in binge eating disorder: a case study
PS02-2063. A randomised–controlled feasibility study of ketamine for the treatment of depression with anorexia nervosa
PS02-2064. Are severe mental illnesses associated with dementia and ischemic stroke across age groups? findings from the PADRIS-PRESTO Cohort
PS02-2065. Environmental exposure to glyphosate and depressive symptoms: inflammatory mediation by TNF-α in a community-based study
PS02-2066. Changes in suicide rates across COVID-19 phases by sex and age group: a population-based time-series analysis
PS02-2067. Association between folic acid prescription and suicide deaths among young adults in Sweden
PS02-2068. Evolution of clinical and treatment patterns among Syrian refugees: a comparative study from 2019 to 2025
PS02-2069. Peer bullying in adolescents with gender dysphoria: a comparison with clinical and non-clinical controls — preliminary findings
PS02-2070. Psychiatric correlates of prospectively confirmed premenstrual dysphoric disorder in individuals assigned female at birth with early-life trauma
PS02-2071. A framework for evaluating effects of hormonal contraception on hippocampal volume and its relation to memory function in healthy women
PS02-2072. Microbial metabolites as regulators of neuroimmune response: unravelling mechanisms of host-microbiome interaction using human induced pluripotent stem cells
PS02-2073. Gut microbiome profiles and treatment response in treatment-naive children with ADHD
PS02-2074. Restoring balance: how the ketogenic diet mitigates the long-lasting effects of prenatal stress
PS02-2075. Divergent kynurenine metabolite profiles and neuroproliferative mechanisms in long COVID-19 patients with and without depression
PS02-2076. Relapsing paediatric acute-onset neuropsychiatric syndrome presenting with obsessive–compulsive symptoms, tic-like behaviours and psychotic-like experiences: a case report
PS02-2077. Associations between immuno-metabolic dysregulation and functional connectivity of corticostriatal and insular circuits in depressive and anxiety disorders
PS02-2078. Multivariate brain morphological–immune patterns underlying internalizing and externalizing behaviour during development
PS02-2079. Anti N-methyl-D-aspartate receptor encephalitis: a diagnosis to consider for first-episode psychosis: a case report
PS02-2080. Therapeutic and adverse effects of interleukin 6 receptor inhibition on depression and schizophrenia: a drug-target Mendelian randomisation study
PS02-2081. Seronegative limbic encephalitis with cytoplasmic antinuclear antibody positivity as a marker of paraneoplastic autoimmunity
PS02-2082. Selective processing speed impairment in body dysmorphic disorder: a Wechsler Adult Intelligence Scale investigation
PS02-2083. A comprehensive investigation of social cognition in body dysmorphic disorder
PS02-2084. Comparing two transcranial magnetic stimulation protocols over the left orbitofrontal cortex: an augmentation strategy for treatment-resistant obsessive-compulsive disorder
PS02-2085. Negative interaction between ceftriaxone and accelerated rTMS: implications for glutamatergic modulation in treatment-resistant depression
PS02-2086. Glucocorticoid receptors and oligodendrocyte precursor NG2-cells as potential molecular targets in the pathophysiology of depression and stress-related disorders
PS02-2087. Elevated monoamine oxidase A in the prelimbic cortex: role in neurotransmission and emotional behaviour
PS02-2088. Sex-specific trajectories of inflammatory markers and depressive symptoms across adolescence: a 3-year follow-up study
PS02-2089. Elevated skin advanced glycation end products in acute bipolar mania: interim pilot findings
PS02-2090. Accelerated cellular aging and cognitive dysfunction in perimenopausal women with bipolar disorder
PS02-2091. Estradiol-immune interaction in male depression
PS02-2092. Exploring the interplay of cognitive vulnerability in major depressive disorder: independent attention bias vs. sequential interpretation–memory chain
PS02-2093. Improved diagnosis of bipolar versus unipolar depression by AI-based multimodal behavioural analysis
PS02-2094. Network-based assessment of plasticity predicts vulnerability to depressive symptomatology in healthy individuals
PS02-2095. Actigraphy-derived physical activity profiles in bipolar disorder: results from the bipcom project
PS02-2096. Joint association of continuity of care and medication adherence with psychiatric readmission in mood disorders: a nested case–control study
PS02-2097. A network-based measure of plasticity in major depressive disorder: investigation of contextual and biological moderators
PS02-2098. Reduced putamen dopamine transporter availability independently predicts major depressive disorder diagnosis
PS02-2099. Phase-specific interhemispheric connectivity alterations in bipolar disorder
PS02-2100. Cognition meets connectivity: clinical and fMRI-based prediction of functional recovery in major depressive disorder
PS02-2101. Evaluating the brain age gap in lithium responder and non-responder patients with bipolar disorder using CentileBrain
PS02-2102. Emotional processing and neural correlates of esketamine response in depressive disorders: a longitudinal fMRI study
PS02-2103. Neurocognition and neuroimaging differences across bipolar disorder with and without psychotic features and schizophrenia
PS02-2104. High-density EEG during electroconvulsive therapy-induced seizures and other brain states: frequency evolution through time
PS02-2105. Autistic-like traits and longitudinal changes in health-related quality of life among patients with bipolar disorder: a 12-month study
PS02-2106. Emergence of treatment-resistant depression after epilepsy surgery: a case report and mechanistic considerations on limbic network disruption
PS02-2107. From slow to fast? Longitudinal dynamics of processing speed across CBT treatment for depression
PS02-2108. Internalised stigma, social functioning and quality of life in severe mental disorders: the moderating role of social support
PS02-2109. Concomitant benzodiazepine use and outcomes of electroconvulsive therapy in major depressive disorder: a nationwide register study
PS02-2110. Longitudinal cognitive and depressive symptom trajectories during ECT: the role of patient vs. treatment factors
PS02-2111. Trajectories of social cognition during esketamine treatment in treatment-resistant depression with and without borderline personality disorder
PS02-2112. Deliberate self-harm and impulsivity trajectories during intranasal esketamine in borderline personality disorder comorbid with treatment-resistant depression
PS02-2113. Efficacy and safety of NH102 in major depressive disorder: a randomised, phase 2 proof-of-concept clinical trial
PS02-2114. Treatment trends in bipolar mania and discrepancies between clinical practice and guideline recommendations in Bavarian psychiatric clinics
PS02-2115. Adjunctive lumateperone 42 mg treatment in major depressive disorder: efficacy across patient-reported depression symptoms
PS02-2116. Real-world post-treatment durability of esketamine nasal spray effectiveness in treatment resistant depression: results from the ECHO non-interventional cohort study
PS02-2117. Real-world effectiveness of esketamine nasal spray in treatment resistant depression: results from the ECHO prospective non-interventional cohort study
PS02-2118. Predictors of response with adjunctive lumateperone in patients with major depressive disorder: a pooled analysis of 2 phase 3 trials
PS02-2119. Major depression in young adults – data from a Bavarian pharmacovigilance project
PS02-2120. Depressive symptoms following interferon-free direct-acting antiviral treatment in patients with hepatitis C: a systematic review and meta-analysis
PS02-2121. Comparison of intranasal esketamine versus other pharmacological strategies in treatment-resistant depression with high suicide risk
PS02-2122. A novel series of small molecule TrkB modulators demonstrating potent neuroplastic and antidepressant effects in preclinical models
PS02-2123. Demographic and clinical characteristics of participants receiving COMP360 psilocybin treatment for treatment-resistant depression across two pivotal phase 3 trials
PS02-2124. Pharmacological augmentation during disorder-specific psychotherapy for chronic and treatment-resistant depression: a retrospective cohort study
PS02-2125. Efficacy and safety of inhaled mebufotenin (GH001) in patients with bipolar II disorder and a current major depressive episode
PS02-2126. Serositis as a rare complication of clozapine treatment: case report
PS02-2127. Structural–diffusion brain topology reveals affective and sleep-related subtypes in bipolar disorder
PS02-2128. Domain-specific associations between childhood trauma and resilience in mood disorders: the central role of emotional neglect
PS02-2129. Inhaled mebufotenin (GH001) improves quality of life across multiple domains in patients with treatment-resistant depression
PS02-2130. Inhaled mebufotenin (GH001) is associated with rapid improvement in symptoms of anhedonia in treatment-resistant depression
PS02-2131. Associations between transdiagnostic polygenic liability and antidepressant outcomes in major depressive disorder
PS02-2132. Biopsychosocial predictors of resilience in bipolar disorder during a global crisis
PS02-2133. Cognitive mechanisms of behavioural activation: early reduction in aversive Pavlovian bias mediates anhedonia improvement in clinical settings
PS02-2134. Cognitive subgroups among individuals with serious mental illness and differences in global functioning
PS02-2135. Methotrexate impairs spatial memory and induces dose-associated neurodegeneration in rats
PS02-2136. Targeted activation of the dorsolateral striatum improves spatial memory performance in a mouse model of alzheimer’s disease
PS02-2137. Cargo-specific regulation of microglial Aβ phagocytosis by lipid-responsive transcription factor SREBF2
PS02-2138. Expanding the horizon of Alzheimer's risk: the independent impact of WMH volume and location
PS02-2139. Predicting progression from subjective cognitive decline to dementia using different neuropsychological criteria: a longitudinal study
PS02-2140. Subtype-specific efficacy and safety of psychotropic medications across major dementias – a literature review
PS02-2141. GLP-1 receptor agonists in neurodegenerative diseases: translational evidence and clinical potential
PS02-2142. Oxyresveratrol reduces α-synuclein aggregation in a Caenorhabditis elegans model with a non-linear dose-response profile
PS02-2143. Psychotic depression as initial presentation of Parkinson’s disease: an interdisciplinary case report
PS02-2144. Localised remyelination therapy for hearing-in-noise disorders: a first-in-class approach to protecting cognitive and mental health
PS02-2145. Clinical characteristics of individuals with attention-deficit/hyperactivity disorder and co-occurring substance use disorder: a systematic review and meta-analysis
PS02-2146. Hand tremor in adults with attention-deficit hyperactivity disorder: clinical and substance-related correlates
PS02-2147. Peripheral blood miRNA profiling by next-generation sequencing identifies a three-marker diagnostic panel for regressive autism spectrum disorder
PS02-2148. Differential expression analysis of the ZNF584 gene in children with autism spectrum disorder
PS02-2149. Differentiating adolescents with suicide attempts from those with suicidal ideation in an emergency neuropsychiatric setting
PS02-2150. Interplay of premenstrual syndrome, sensory processing, and ADHD symptom severity in adult women
PS02-2151. Severe autism phenotype and functional impairment in Tonne–Kalscheuer syndrome
PS02-2152. Electroencephalography-based evaluation of cognitive training outcomes in children with attention-deficit and hyperactivity disorder
PS02-2153. Relationship between reading–writing performance and executive functions, neurocognitive profile and functionality in children with SLD and comorbid ADHD
PS02-2154. Testing the validity of a digital diagnostic instrument: neurodevelopmental diagnoses in a South African sample of 178 children
PS02-2155. The dynamic response of intrinsic connectivity networks to low-dose psilocybin during face matching in autistic adults
PS02-2157. Successful management of sleep disturbance and attention deficit hyperactivity disorder symptoms with melatonin and methylphenidate in Smith-Magenis syndrome
PS02-2158. Emotion dysregulation in adults with ADHD: associations with age, sex, menopausal status, substance use, and exposure to violence
PS02-2159. Signals versus synchrony: decoding affective processing from voxel activation versus functional connectivity in task-based functional magnetic resonance imaging
PS02-2160. Persistent cognitive complaints following SARS-CoV-2 infection, clinical profiles, predictors, and voxel-based morphometry analysis of structural neuroimaging data
PS02-2161. Transdiagnostic resting-state fMRI biotypes in early psychosis and depression predict cognitive deficits and functional outcomes
PS02-2162. Cross-pipeline consistency of automated brain morphometry in mild cognitive impairment and Alzheimer’s disease
PS02-2163. Eyes-closed episodes during eyes-open resting-state functional MRI: prevalence and temporal characteristics of unintended sleep onset in healthy participants
PS02-2164. Exploring cellular, neuroinflammatory and neurotransmitter-based mechanisms of blood-brain barrier leakage in schizophrenia-spectrum disorders
PS02-2165. Age-related alterations of local gyrification index in female patients with schizophrenia: a surface-based morphometry study
PS02-2166. Neural correlates of semantic similarity and associations with GABA and glutamate in the Left Inferior Frontal Gyrus
PS02-2167. Rewiring motivation: a landmark case of transplant-induced recovery from chronic apathy in Wilson’s disease
PS02-2168. Quality of sleep (QoS) in chronic migraine women during reproductive period treated with monoclonal antibodies – 6-months follow-up
PS02-2169. Prenatal VPA exposure impairs pair-pulse induced LTD at the synaptic level without altering spiking output in the dentate gyrus
PS02-2170. Behavioural investigation of the effects of different forms of long term depression on the erasure of learned hippocampal spatial information
PS02-2171. Enhanced long-term depression in schizophrenia-associated TCF4 transgenic mice is NMDA receptor-mediated
PS02-2172. Profiling of microglia and neurons in a stem cell and murine model of anorexia nervosa
PS02-2173. Neurocognitive functions and social cognition in bipolar disorder, attention deficit hyperactivity disorder, and comorbid bipolar disorder–attention deficit hyperactivity disorder
PS02-2174. Carpal tunnel syndrome, psychological and cognitive impact in addition to sensory motor Vegetative Symptoms
PS02-2175. The negative factor of stigma
PS02-2176. Randomised–controlled trial of transcranial direct current stimulation as augmentation to cognitive training in Alzheimer's disease
PS02-2177. Randomized–controlled pilot study of tDCS and prism adaptation in adult ADHD: effects on working memory and executive functions
PS02-2178. Neurostimulation approaches to cognitive aging: effects of transcranial magnetic stimulation on working memory networks
PS02-2179. Dimensional psychopathology profiling during psychiatric intake: implementation and preliminary clinical target mapping
PS02-2180. Altered olfactory processing in schizophrenia: a sensory signature of clinical severity
PS02-2181. Impact of pre-existing mental health conditions on obstetric and neonatal outcomes
PS02-2182. Maternal TNF gene expression and clinical functioning during pregnancy: a longitudinal multi-domain analysis
PS02-2183. Third trimester inflammatory signature predicts peripartum depression and reveals divergent brain-immune relationships
PS02-2184. Beyond maternal risk: paternal bonding and perinatal depressive symptoms
PS02-2185. Integrative multilevel model for diagnosis and risk stratification of perinatal mental disorders
PS02-2186. The mental health of mothers of infants with life-threatening bronchiolitis: what is the role of hormones?
PS02-2187. Prazosin in pregnancy: treating post-traumatic stress disorder in the absence of evidence
PS02-2188. Impact of comorbid borderline personality disorder on medication exposure and healthcare utilisation in bipolar disorder
PS02-2189. Blind to feelings, lost in self: alexithymia and personality dysfunction in suicidality
PS02-2190. Clinical and genetic characteristics of patients exposed to high-dose selective serotonin reuptake inhibitors (SSRIs) in UK Biobank
PS02-2191. Peripheral blood RNA-seq analysis in bipolar and schizophrenia spectrum disorders: modest influence of antipsychotic treatment
PS02-2192. A systematic review of 100 studies investigating pharmacological effects on human aversive memory
PS02-2193. Longitudinal cytokine remodeling in antipsychotic-naïve paediatric patients treated with second-generation antipsychotics: evidence for a biphasic immunomodulatory response
PS02-2194. A naturalistic, descriptive study of treatment response to ketamine or esketamine in patients with treatment-resistant depression
PS02-2195. What does auditory oddball electroencephalography (not) reveal about arbaclofen treatment response in a clinical trial of autism?
PS02-2196. Pharmacological perturbation of brain dynamics: effects of esketamine and midazolam on metastability
PS02-2197. Clinical characterization and real-world management of patients treated with intranasal esketamine in a tertiary treatment-resistant affective disorders unit
PS02-2198. Effects of GLP-1 receptor agonists on craving and compulsive consumption in substance use and binge eating disorders: a systematic review
PS02-2200. Real-world functional improvements in treatment-resistant depression: a prospective study of intranasal esketamine
PS02-2201. Effectiveness of risperidone ISM in adult patients with acute schizophrenia: an age subgroup analysis from the RESHAPE study
PS02-2202. The formation of dopamine and serotonin in a CYP2D6-humanized rat brain
PS02-2203. Kochia scoparia seed extract ameliorates anhedonia and social interaction deficits in a D-galactose-induced aging model
PS02-2204. Revisiting ketamine’s rapid antidepressant effect beyond NMDA antagonism: modulation of endogenous opioid signaling and interactions with glutamatergic-driven neuroplasticity
PS02-2205. Monoamine oxidase inhibition preferentially elevates trace amines over classical monoamines in rodent brain: a meta-analysis
PS02-2206. Trace amine-associated receptor 1 as a target for monoaminergic activity enhancers: cyclic adenosine monophosphate profiling of 1-(indol-3-yl)-2-propylaminopentane versus beta-phenethylamine
PS02-2207. Xanomeline/Trospium and suicide-related events in schizophrenia: an early pharmacovigilance analysis
PS02-2208. A pharmacometric framework for norepinephrine transporter occupancy and dose equivalence across psychotropic medications
PS02-2209. Prolonged blurred vision as a side effect of intranasal esketamine administration in treatment-resistant major depressive disorder: a case report
PS02-2210. Therapeutic adherence promotion program for severe mental illness: the ADHERA study protocol
PS02-2212. Energy-Related symptom phenotype is associated with immuno-metabolic dysregulations in bipolar disorder: a data-driven approach
PS02-2214. Functional genomics to identify the transdiagnostic biosignatures underlying treatment resistance across major psychiatric disorders in the Psych-STRATA consortium
PS02-2215. PreDiction of trEatment response and clinicaL outcome in First episode psYchosis: from braiN imaging to molecular biology: DELFYN PROTOCOL
PS02-2216. Cross-sectional and longitudinal effects of visceral adipose tissue on brain aging and cognition - a sex differences perspective
PS02-2217. Vitamin D measurement and supplementation prescribing amongst adolescent psychiatric inpatients within a UK mental health trust: a re-audit
PS02-2218. The psychedelic 25C-NBF displays 5-HT2A receptor selectivity and enables in silico prediction of ligand selectivity
PS02-2219. Intranasal esketamine leading to rapid remission in treatment-resistant major depressive disorder after multiple treatment failures
PS02-2221. Effects of Amanita muscaria extract on brain monoamines and potential applications in the treatment of neurodegenerative diseases
PS02-2222. Distinct temporal dynamics of the psilocybin experience differentially relate to positive and distressing subjective effects
PS02-2223. Mapping the multi-modal landscape of psychiatric disorders through integrative neurogenetics
PS02-2224. Brain gene expression-informed analysis identifies retinoid receptor targets in suicidal thoughts and behaviours
PS02-2225. Psychosocial interventions for emotion dysregulation across populations: a systematic review and network meta-analysis
PS02-2226. Association between high-potency cannabis consumption and risk of offending behaviours in a two-year first-episode psychosis cohort
PS02-2227. Neural correlates of comorbid depression in schizophrenia spectrum disorders: a multi-sample machine learning study
PS02-2228. Large language model-assisted screening of positive and negative syndrome scale items in first-person accounts of schizophrenia spectrum disorders
PS02-2230. Age-dependent DNA methylation changes at FKBP5 enhancer sites are associated with increased cortical gene expression in schizophrenia
PS02-2231. Full blood count data for clustering in clinical high risk (CHR) for psychosis individuals: validation of unsupervised and semi-supervised approaches
PS02-2232. Tendency towards association between a single nucleotide polymorphism in the insulin–insulin-like growth factor 2 transcript and schizoaffective disorder
PS02-2233. At the interface of psychosis and neurodegeneration: red flags in very-late-onset psychosis: insights from five cases
PS02-2234. Environmental risk factors and blood-brain barrier dysfunction in a dual-hit model of schizophrenia
PS02-2235. Longitudinal changes in striatal regional homogeneity and their clinical correlates in treatment-resistant schizophrenia
PS02-2236. Parkinsonism and psychopathology severity in real-world outpatients with schizophrenia: a PRISM analysis
PS02-2237. A mind unravelling: a case report of adult adrenoleukodystrophy
PS02-2238. Early visual processing in schizophrenia spectrum disorders: a systematic review and meta-analysis of the P1 component
PS02-2239. Efficacy and tolerability of transcranial electrical stimulation (tES) in schizophrenia: a systematic review, meta-analysis, and meta-regression analysis of sham response
PS02-2240. Brexpiprazole in early- and late-onset psychotic disorders with complex neurodevelopmental and medical comorbidities: a case series
PS02-2241. Clinical improvement in psychosis during home hospitalisation: association with treatment attitude
PS02-2242. Design and updates of the phase-3, potentially pivotal, ENIGMA-TRS program: the global study of evenamide in treatment-resistant schizophrenia
PS02-2243. Injection site reactions and local tolerability with subcutaneous long-acting injectable olanzapine (TV-44749) in schizophrenia: phase 3 SOLARIS trial results
PS02-2244. Long-term quality of life of adults with schizophrenia treated with subcutaneous long-acting injectable olanzapine (TV-44749): SOLARIS phase 3 results
PS02-2245. Patient and caregiver preferences for long-acting injectable treatments in schizophrenia: a discrete choice experiment
PS02-2246. Exposure–response efficacy and safety analysis of subcutaneous LAI olanzapine (TV-44749): clinical application for dosing and switching strategies
PS02-2247. Joint population pharmacokinetic model of olanzapine following oral, intramuscular, and subcutaneous administration to support TV-44749 dose recommendations and switching strategies
PS02-2248. Insulin resistance as a predictor of cognitive decline following a first episode of psychosis: a 1- and 2-Year follow-up study
PS02-2249. Self-reported interoceptive sensitivity and heartbeat task performance in psychotic patients and healthy controls: evidence from a source monitoring study
PS02-2250. Longitudinal stressor reactivity trajectories reveal risk profiles across early psychotic and affective disorders
PS02-2251. Autonomic regulation via dermal vibrotactile triggering of piezoelectric channels: an emerging nonmedication approach to symptom relief
PS02-2252. Circadian factors and coping strategies are central to the expression of PTSD symptoms in post-war soldiers
PS02-2253. Dream features as a predictor of subjective sleep features: a comparison with standard EEG activity metrics
PS02-2254. Association of obstructive sleep apnea with body mass index, sleep duration, and depression outcomes in Korean adults
PS02-2255. Daridorexant intervention in non-invasive positive pressure ventilation treatment for patients with comorbid insomnia and obstructive sleep apnea: a study protocol
PS02-2256. Subordination experiences disrupt network adaptivity, biasing negative hippocampal recall
PS02-2257. Autolobotomy: a case study
PS02-2258. Age-dependent effects of oxytocin on corticosterone-induced behavioral alterations and weight gain in male rats
PS02-2259. Burnout and well-being among Thai medical educators: a national survey by psychiatric speciality
PS02-2260. Working memory deficits and brain network reconfigurations following stress in major depressive disorder with childhood trauma
PS02-2261. Brain network centrality following stress in adults with major depressive disorder and childhood trauma
PS02-2262. Child maltreatment profiles differentially predict lifetime but not acute suicidality in high-risk disorders
PS02-2263. Changes in locus coeruleus signal intensity and whole-brain functional connectivity in Alzheimer's disease patients
PS02-2264. The associations between perceived expressed emotion, digital game addiction, internet addiction, and anxiety disorders in adolescents
PS02-2265. Psilocybin suppresses inflammatory signalling and restores neuroplasticity in a dexamethasone-induced neuroinflammatory neurosphere model
PS02-2266. MTHFR burden-associated DNA methylation patterns in SSRI response in major depressive disorder
PS02-2267. Interindividual variability in sensitivity to light synchronisation effects and circadian characterization of individuals
PS03-3001. Persistent effects of repetitive transcranial magnetic stimulation on reducing voluntary ethanol consumption in adult rats following adolescent drug exposure
PS03-3002. Neurobiological subtypes in alcohol use disorder and their phenotypic and clinical profiles
PS03-3003. Non-medical use of drugs and adverse childhood experiences in a community sample
PS03-3004. Characteristics of current online gaming overusers in Gangwon state in Korea
PS03-3005. The impact of acute alcohol use and usual drinking frequency on the clinical characteristics and medical severity of suicide attempts
PS03-3006. Investigating reward-based learning across alcohol use severity
PS03-3007. Thinking about stopping: the effects of atomoxetine on cognitive impulsivity in human cocaine addiction
PS03-3008. Brexpiprazole vs aripiprazole in schizophrenia with comorbid substance use disorder: impulsivity and craving outcomes
PS03-3009. A scalable systematic RDoC multi-omics framework to reorganize preclinical psychiatric research beyond diagnostic categories
PS03-3010. Cognitive training under altitude-like hypoxia improves cognition in mice: results from the ALTIBRAIN preclinical trials
PS03-3011. Modulation of glucocorticoid signalling by a ketogenic diet in a prenatal stress model
PS03-3012. Changes in social behavior and prefrontal cortex transcriptomics in a diabetes type 2 model in aging male rats
PS03-3014. Long-term Perampanel treatment during epileptogenesis attenuates cognitive impairment and regulates hippocampal Neurokinin B expression in a rat model of epilepsy
PS03-3015. Fimasartan ameliorates cognitive impairment in a scopolamine-induced Alzheimer’s disease model in rats
PS03-3016. Omega-3 and membrane lipids supplementation during adolescence improves cognitive function and preserves prefrontal cortex integrity in preclinical model
PS03-3017. In vivo occupancy of psilocybin and LSD at serotonergic receptors and the serotonin transporter in pigs using PET imaging
PS03-3018. Prenatal stress shapes astroglial marker expression across developmental stages in rats
PS03-3019. Neuroprotective effects of vincamine on cranial irradiation-induced cognitive impairment in mice
PS03-3020. Entropic curvature on hyperbolic semantic manifolds indexes anxiety-like cognitive dynamics: an interpretable geometric biomarker
PS03-3021. Electrocortical function at rest and during emotion processing in the 7.5% carbon dioxide model of anxiety
PS03-3022. Family-history variables are associated with remission in the OLIVE trial
PS03-3023. Adiposity tunes anxiety-related behaviours through insular cortex dysregulation in mice
PS03-3024. Do hormonal contraceptives impact avoidant behaviour among women with severe somatic and psychiatric conditions? – A comparative study
PS03-3025. Anger expression and social anxiety are associated with dissociable neuroendocrine and inflammatory biomarker patterns: preliminary evidence from a cross-sectional study
PS03-3026. Affective context shape confidence and motivated task behavior irrespective of objective performance
PS03-3027. Dynamic belief updating in anxiety disorders during a predictive inference task with functional magnetic resonance imaging
PS03-3028. Atypical selective mutism in the context of sibling rivalry: an early childhood case report
PS03-3029. Assessment of electrocardiographic cardiac arrhythmia risk markers in drug-free patients with generalized anxiety disorder: preliminary findings
PS03-3030. Associations between obsessive-compulsive personality disorder and sleep quality in individuals with anxiety and mood disorders
PS03-3031. Comparative effectiveness of cognitive behavioural therapy and selective serotonin reuptake inhibitors in moderate generalised anxiety disorder in primary care
PS03-3032. Elexacaftor/Tezacaftor/Ivacaftor impact on anxiety symptoms in cystic fibrosis: a systematic review
PS03-3033. Artificial intelligence as a confirmatory medium in the development of first-episode psychosis: a case report
PS03-3034. Enhancing depression screening with machine learning by addressing class imbalance in a nationally representative south korean survey
PS03-3035. Facial emotion recognition using dynamic virtual avatars in schizophrenia and bipolar disorder: findings in immersive and non-immersive virtual reality
PS03-3036. Phenotyping thought disorder in treatment-resistant schizophrenia: a multidimensional analysis using the thought and language disorder scale and clinical correlates
PS03-3037. Case series of generative artificial intelligence-related suicide and rising lawsuits in adults
PS03-3038. Brain structural signatures in schizophrenia patients and their siblings: evidence for an intermediate phenotype from an interpretable machine-learning multicohort analysis
PS03-3039. Towards in silico modeling of psychosis: NMDA-Mg2+ dynamics and auditory sequence learning in a spiking neural network
PS03-3040. Reconfiguring the brain-personality interactome across the psychosis spectrum: the role of early life adversity
PS03-3041. An ECNP-led global biomarkers mapping project across anxiety, depression and psychosis disorders: an umbrella systematic review
PS03-3042. MitomiR-5 is associated with mitochondrial biogenesis and illness burden in bipolar disorder
PS03-3043. Sex-specific gene expression and genetic predisposition for depression in the EMBER-MDD study
PS03-3044. Impulsivity in bipolar disorder as influenced by mood state and alcohol/substance use disorder comorbidities: a systematic review and meta-analysis
PS03-3045. Upregulation of inflammatory proteins as a systemic immune activation in major depressive disorder
PS03-3046. The relationship between serum FGF-21 and GDF-15 levels and cognitive functioning in a healthy population
PS03-3047. Impact of lithium and valproic acid on telomere length in patient-derived lymphoblastoid cell lines
PS03-3048. Peripheral inflammasome activity and domain-specific behavioural associations in preschool children with autism spectrum disorder
PS03-3049. Pre-stimulation corticomuscular coherence as a candidate marker of responsiveness to individualised beta-frequency continuous theta burst stimulation
PS03-3050. Global stakeholder engagement for mapping psychiatric biomarkers: an ECNP-led international initiative for precision psychiatry
PS03-3051. Dynamic redox profiling in aneurysmal subarachnoid haemorrhage identifies glutathione reductase deficit in delayed cerebral ischemia
PS03-3052. Non-coding RNA expression and exposure to childhood adversity: a systematic review of the human literature
PS03-3053. The relationship between drug-induced Parkinsonism observed in patients with schizophrenia and serum levels of GDNF family ligands
PS03-3054. Melanocortin peptides and metabolic control: γ-MSH vs α-MSH in MC3R–GHSR1A signaling
PS03-3055. Altered beta-arrestin-dependent regulation of a human obesity-associated melanocortin 3 receptor variant
PS03-3056. Translational characterization of oxidative stress-induced nucleic acid damage and mitochondrial function during antidepressant exposure
PS03-3057. Evening chronotype and internet addiction in university students: the mediating role of attention-deficit/hyperactivity disorder symptoms
PS03-3058. First results of the DynAMoND study: mapping distinct patterns of affective dysregulation in ADHD, bipolar disorder, and borderline personality disorder
PS03-3059. GRIP-Canada (Guide to Recommendations and Indications in Psychopharmacology): development of a structured, evidence-based framework for psychopharmacological decision support
PS03-3060. Relational processes in face-to-face and videoconferencing psychiatric interviews with young people: a multimodal analysis
PS03-3061. Central amygdala neuronal ensembles contribute to food-related conflict in a novel eating disorder model
PS03-3062. Protein-enriched diet modulates anxiety-like and metabolic adaptations in anorexia nervosa-like mice
PS03-3063. Metacognitive processes and affective symptoms associated with postoperative eating dysregulation following bariatric surgery
PS03-3064. Efficacy and safety of COMP360 psilocybin therapy in anorexia nervosa: a proof-of-concept study
PS03-3065. Lifetime substance use disorder and suicidal behaviour: a population-based familial co-aggregation register study
PS03-3066. Medicine use preceding fatal poisonings among individuals with bipolar disorder
PS03-3067. Association between lonliness, social isolation, and suicidality
PS03-3068. Anhedonia in the general population: its impact on eating behaviours and psychological dimensions
PS03-3069. Disentangling the epigenetic landscape of saliva: a genetically informed longitudinal twin study of DNA methylation
PS03-3070. Socio-environmental, psychological and digital determinants of suicidal ideation and behavior among Tunisian adolescents: a cross-sectional study
PS03-3071. Gender disparities in family functioning scales: psychometric study of 270 sexually compulsive individuals using FACES III, BT, and GARF
PS03-3072. All that glitters is not gold: shifting referral pathways and diagnostic yield in adult autism assessment
PS03-3073. Mechanophilia and early emotional deprivation
PS03-3074. Gut microbiota modulation by ketamine compounds: a preclinical systematic review with clinical sample data
PS03-3075. Refining gut microbial signatures of depressive symptoms through meta-analysis across population studies: effects of sex and age groups
PS03-3076. Gut microbiome dysbiosis in early Alzheimer’s disease and mild cognitive impairment: a systematic review
PS03-3077. Immune-related correlates of cognitive variability in bipolar disorder: a multiblock partial least squares analysis
PS03-3078. Cerebral white matter integrity in type 2 diabetes mellitus: underlying mechanisms and associations with anhedonia, melancholia, and cognition
PS03-3079. Steroid-responsive autoimmune encephalopathy presenting as treatment-resistant depression
PS03-3080. Case report: Anti Yo encephalitis - psychiatric presentation
PS03-3081. Investigation of the relationship between neurocognitive and social cognitive functions and peripheral inflammatory markers in patients with schizophrenia
PS03-3082. Symptom severity in childhood-onset obsessive-compulsive disorder
PS03-3083. Dual-SSRI combinations in ultra-resistant obsessive–compulsive disorder: a real-world observational pilot study
PS03-3084. Characterization of an epigenetic model of depression linked to neuroinflammation and impaired neuroplasticity
PS03-3085. Behavioural and metabolic phenotyping of the Flinders Sensitive Line rat in inflammation-associated depression
PS03-3086. Rapid and sustained antidepressant-like effects of hallucinogenic and non-hallucinogenic serotonergic compounds in a chronic social defeat model
PS03-3088. The evidence for venlafaxine to treat generalized anxiety disorder in Japanese patients: fulfilling a significant unmet need
PS03-3089. Psychopharmacological management and early symptom improvement in chronic oral pain: treatment patterns and outcomes after integrated psychiatric care
PS03-3090. Long-term effectiveness and tolerability of vortioxetine in a naturalistic outpatient sample
PS03-3091. AI-driven multi-omics and genetic causal inference implicate immune proteins in major depression
PS03-3092. Risk stratification of 12-month suicidal risk in bipolar disorder with three different clustering algorithms
PS03-3093. Gut microbiota signatures associated with lithium treatment and clinical response in patients with bipolar disorder
PS03-3094. Analysis of plasma extracellular vesicle microRNAs in major depressive disorder and treatment-resistant depression
PS03-3095. Cortisol awakening response and outcomes after intranasal esketamine in treatment-resistant depression
PS03-3096. Extracellular vesicle–derived microRNA profiling in bipolar disorder and in response to lithium treatment
PS03-3097. A plasma lipidomic endophenotype for bipolar disorder: evidence from unaffected siblings
PS03-3098. Coupled bioenergetic and network dysfunction in hippocampal neurons associated with suicide in bipolar disorder
PS03-3099. Studies on neurochemical mechanisms underlying non-response to antidepressants in a rat Chronic Mild Stress model of treatment-resistant depression
PS03-3100. Investigating the role of diacylglycerol kinase eta in bipolar disorder and lithium response
PS03-3101. Can smartphones detect mood? Investigating temporal dynamics in passive sensing data from bipolar patients
PS03-3102. Affective state-specific speech biomarkers in bipolar disorder: signal-loss in depression and signal-gain in mania
PS03-3103. Lifetime suicidal ideation is associated with depressive symptom level and variability in a Korean longitudinal cohort
PS03-3104. Comparison of depressive and anxiety symptom networks by allergic rhinitis status: a nationwide population-based study using KNHANES
PS03-3105. Forecasting disease trajectory based on baseline characteristics and symptom dynamics of patients with recurrent major depressive disorder
PS03-3106. Immune-mediated disease and risk of depression across the life-course: results from the ALSPAC and UK Biobank cohorts
PS03-3107. Insights into inflammatory depression: investigating the relationship between plasma short-chain fatty acids, inflammatory markers, and depressive symptoms
PS03-3108. Brain-immune system interactions in major depression: role of β2-adrenergic receptor in myeloid and lymphoid cells
PS03-3109. Differentiation of bipolar and unipolar depression using neuroimaging, immune-inflammatory and transcriptomic signatures: a machine learning approach
PS03-3110. Delirium mimicking psychiatric relapse in older adults: a case-based analysis of diagnostic bias
PS03-3111. Impact of weather, sleep and physical activity on daily affective fluctuations: an ecological momentary assessment study
PS03-3112. Resting-state functional connectivity correlates of suicidal ideation in major depressive disorder: associations with suicidal ideation severity and childhood trauma
PS03-3113. Resting state connectivity correlates of treatment resistant depression
PS03-3114. Why does It feel so intense? A novel approach to neurofunctional alterations in MDD
PS03-3115. New-onset apathy in bipolar disorder: a clinical warning for encephalitis
PS03-3116. The impact and neurophysiological mechanisms of acupressure on mental wellbeing in young adults
PS03-3117. Mapping emotion dysregulation in bipolar disorder: links to cognition and functional impairment
PS03-3118. Functional outcomes following cognitive remediation (INCREM) versus psychoeducation in a multicentre study: the role of site heterogeneity
PS03-3119. Selective cytokine alterations in depression: reduced IL-8 and its association with chronic stress
PS03-3120. Treatment adherence, stigma, and help-seeking among fasting and non-fasting psychiatric outpatients during ramadan
PS03-3121. Transcutaneous vagus nerve stimulation enhances reward-effort efficiency in major depressive disorder
PS03-3122. Hippocampal transcriptomic profiling after electroconvulsive stimulation in adolescent male and female rats
PS03-3123. The effects of a mindful yoga program on postpartum depression: a randomized controlled clinical trial
PS03-3124. Screening for postpartum depression in Latvia: validation and optimal cut-offs of the PHQ-9 against a structured diagnostic interview
PS03-3127. The efficacy of adjunctive intranasal insulin for the treatment of neurocognitive dysfunction in bipolar disorder
PS03-3128. Real-world effectiveness and treatment duration by psychiatric comorbidity status: esketamine nasal spray for treatment-resistant depression
PS03-3129. Investigating the role of ATG9a-mediated autophagy in shaping stress resilience
PS03-3130. Dextromethorphan combined with bupropion, fluoxetine, or paroxetine in real-world unipolar and bipolar depression: effectiveness, tolerability, and switch risk
PS03-3131. Clinical lithium toxicity despite therapeutic serum levels: a case report
PS03-3132. Prevalence and sociodemographic correlates of antidepressant use in Italian residential care facilities
PS03-3133. Distinguishing chronic and non-chronic depression: a clinical profile and symptom networks approach
PS03-3134. Potential interaction between high protein intake and lithium exposure in renal dysfunction: a case report
PS03-3135. Ayahuasca induced mania in patient with bipolar disorder: case report and targeted literature review
PS03-3136. Dorsomedial prefrontal neurometabolites predict functional remediation outcomes in older adults with bipolar disorder
PS03-3137. Prevalence of bidirectional comorbidity between obstructive sleep apnea and mood disorders: a systematic review and meta-analysis
PS03-3138. Environmental exposures and functional outcomes in bipolar disorder
PS03-3139. From Depression to Dementia: Genetic Variants in APOE and APOC1 Linked to Post-Depression Dementia in the UK Biobank
PS03-3140. When mania is not mania: diagnostic challenges between bipolar disorder and frontotemporal dementia
PS03-3141. Manganese ferrite nanoparticles trigger selective superoxide dismutase-related responses in neuronal models and rat cortex
PS03-3142. Personality changes in sturge weber syndrome: beyond epilepsy, a clinical case
PS03-3143. Differences in delirium management across categories of psychiatry clinicians in Romania
PS03-3144. Frontotemporal dementia case presenting with treatment-resistant malignant catatonia
PS03-3145. Real-world duration of rivastigmine therapy in dementia: oral versus transdermal patch
PS03-3146. Neuroprotective potential of Glucagon-like peptide-1 receptor agonists in Alzheimer’s disease: evidence from preclinical animal studies
PS03-3147. Charles Bonnet syndrome: a great mimicker of late-life psychosis and neurodegeneration
PS03-3148. Late-onset psychosis and catatonia as early manifestations of C9orf72-associated frontotemporal dementia: diagnostic pitfalls and treatment implications
PS03-3149. Language profiles in young help seekers and their association with psychopathology
PS03-3150. Nerve growth factor levels in peripheral blood of children with attention deficit hyperactivity disorder: a meta-analysis
PS03-3151. Assessing the ADHD LANDSCAPE in Women: Results from Female Psychiatric Patients
PS03-3152. Brain–large language model alignment during naturalistic language processing in attention deficit hyperactivity disorder, depression and schizophrenia
PS03-3153. Childhood maltreatment and precuneus/dorsal posterior cingulate cortical thickness in ADHD: a matched-group comparison
PS03-3154. Intact visuospatial working memory capacity in adult attention-deficit/hyperactivity disorder
PS03-3155. The relationship between theory of mind and perceptions of sexual consent in high-functioning autism
PS03-3156. Referral pathways to an adult attention-deficit/hyperactivity disorder outpatient clinic: sociodemographic and clinical correlates
PS03-3157. Differentiating adult attention deficit/hyperactivity disorder from borderline personality disorder: temporal profile and interpersonal specificity of emotional dysregulation
PS03-3158. Attention-deficit/hyperactivity disorder pharmacotherapy in adults: prevalence, clinical profiles, and predictors of treatment modality
PS03-3159. Suicide risk and psychosocial profile in ADHD: a descriptive real-world study
PS03-3160. Neurodevelopmental disorders in the Albanian penitentiary system: findings from the first systematic screening study
PS03-3161. Oxytocin pathway-specific polygenic risk scores are associated with autistic traits in a population-based cohort
PS03-3162. Sex differences in diagnostic accuracy of ADOS-2 Module 4 in adults
PS03-3163. The association of cholesterol with rich-club organisation and global efficiency in the structural connectome
PS03-3164. Comparison of sensitivity for detecting transient striatal dopamine release for different radioligands
PS03-3165. Psychedelics distinctly alter brain entropy and complexity compared to psychostimulants
PS03-3166. Effects of 5-HT2AR modulation on regional homogeneity and interactions with 5-HT2AR binding, a human pharmaco-fMRI and PET study
PS03-3167. Mapping the molecular foundations of neural network alterations in bipolar disorder
PS03-3168. Changes in reward processing following cognitive behavioral therapy: A meta-analysis of response-dependent effects in task-based fMRI studies
PS03-3169. Brain age gap across psychiatric diagnoses: a transdiagnostic comparison of schizophrenia, bipolar disorder type 1, and major depressive disorder
PS03-3170. Can we trust algorithms in sleep research? Evaluating automated sleep spindle detection in simultaneous EEG-fMRI recordings
PS03-3171. Brain dynamics during acute psychosocial stress and its association with physiology and childhood adversity
PS03-3172. Childhood trauma, life events and clinical presentation in functional tic-like behavior and Tourette syndrome: preliminary data from a non-interventional study
PS03-3173. Susceptibility to functional seizures in temporal lobe epilepsy: the interplay between psychological and somatoform dissociation, trauma, and sense of agency
PS03-3174. When more is less: magnesium attenuates the efficacy of memantine in an aged rat model of multiple sclerosis
PS03-3175. Frontal lobe syndromes: a neuropsychiatric review of clinical phenotypes, neurocircuitry, and differential diagnosis
PS03-3176. Toward bedside neuroimaging in schizophrenia: longitudinal monitoring of clinical and cognitive improvement and DMN activity using fNIRS-EEG
PS03-3177. Computational modeling of magnetoencephalographic auditory oddball responses in adolescents at familial high-risk for psychosis
PS03-3178. Maqui berry, inulin and probiotics attenuate ketamine-induced cognitive and hippocampal synaptic alterations in adolescent mice
PS03-3179. Electrophysiological markers of facial emotion processing: an umbrella review integrating magnetoencephalographic and event-related potential evidence in schizophrenia and depression
PS03-3180. Neurocognitive and psychiatric outcomes of parasitic infections
PS03-3181. Clinical and cognitive factors associated with psychosocial functioning in patients with major depressive disorder
PS03-3182. Executive function and functional independence as predictors of quality of life in community-dwelling older adults
PS03-3183. From victimization to perpetration: impulsivity, emotion dysregulation and threat sensitivity across intimate partner violence roles
PS03-3184. Differential contributions of cognitive reserve components to cognition and functioning in early affective and non-affective psychosis
PS03-3185. Psychosocial triggers of non-suicidal self-injury in a clinical sample of adolescents in Albania: pilot study
PS03-3186. Beyond significance: a 10-year analysis of negative findings in ECNP Congress abstracts (2016–2025)
PS03-3187. Multimodal characterization of deep brain stimulation for obsessive-compulsive disorder
PS03-3188. Predictors of prolonged seizures in electroconvulsive therapy: a 10-year retrospective study of 48,571 treatments
PS03-3189. Frontoparietal network-optimised versus standard targeting for bilateral theta-burst stimulation in depression: a naturalistic randomised study protocol
PS03-3190. Validation of UNISI-CAT, a cognitive test battery for early phase drug development trials and biomarker research
PS03-3191. ADHD symptoms, chronotype, and vulnerability to postpartum depression: preliminary results from a two-stage prospective study
PS03-3192. Association between neuroticism and postpartum depressive symptoms in relation to estradiol treatment: preliminary results from the Maternal Mental Health trial
PS03-3193. Clinical state and personality dimensions in unipolar and bipolar depression: a latent class analysis
PS03-3194. Polygenic risk for schizophrenia modifies the real-world effectiveness of antipsychotic treatment in psychotic disorders
PS03-3195. A randomised controlled trial for intranasal oxytocin versus placebo to treat Body Dysmorphic Disorder (BDD)
PS03-3196. Intranasal esketamine in treatment-resistant depression: longitudinal response and remission in real clinical practice
PS03-3197. Real-world esketamine for treatment-resistant depression: induction outcomes from the enTRD registry
PS03-3198. Intranasal esketamine for treatment-resistant depression in older adults (>65 years): a prospective real-world study
PS03-3199. Association between plasma ketamine metabolites and antidepressant response in treatment-resistant depression
PS03-3200. Pharmacological modulation of GABAergic function and behavior in FMR1 knockout mice
PS03-3201. The price of focus: Cognitive doping and its hidden neuropsychiatric costs
PS03-3202. Antipsychotics in monotherapy and cross-sectional symptom burden: analysis adjusted for diagnosis, disease duration, and age
PS03-3203. Clozapine/norclozapine ratio in therapeutic drug monitoring: clinical utility and standardisation challenges
PS03-3205. Effects of Kochia scoparia seed extract on passive-avoidance memory in rats with chronic ethanol exposure
PS03-3206. Lithium orotate in neuropsychiatry: a narrative review of preclinical evidence and clinical gaps
PS03-3207. Effects of Tanacetum vulgare on cognition, anxiety and hippocampal neuroinflammation in a scopolamine-induced model of amnesia
PS03-3208. Energy drinks but not caffeine and taurine components iImpair behavioral and cognitive functions: protective effects of N-acetylcysteine in rats
PS03-3209. Low-dose cariprazine for clozapine-induced constipation and sialorrhea?
PS03-3210. Anticholinergic burden in schizophrenia: associations with symptoms, cognition, and thought disorder
PS03-3211. The burden of antipsychotic treatment for patients with mental health disorders
PS03-3212. How many patients with schizophrenia spectrum disorders need sustained clozapine treatment to save one life? A population-based cohort study
PS03-3214. EDIT-B consortium study: new validation for a blood test for the diagnosis of bipolar disorder
PS03-3215. Self-sampling for improved longitudinal monitoring of lithium treatment
PS03-3216. Epigenetic clocks capture disease burden in early psychosis
PS03-3217. Blue-light blocking glasses as adjunctive treatment reduce depressive symptoms and sleep latency in older adults: a pilot exploratory study
PS03-3218. Enhancing the therapeutic relationship in an acute mental health unit
PS03-3219. Psilocybin acutely alters circulating micro-RNA expression, and predicts condition-specific biomarker dissociation in healthy volunteers
PS03-3220. 5-methoxy-N,N-dimethyltryptamine induces a rapid multi-level neuroplastic cascade in mouse primary cortical neuron–astrocyte cultures
PS03-3221. Sex differences in the cognitive effects of repeated low-doses of LSD: a randomised, placebo-controlled study
PS03-3222. Disentangling pharmacological and experiential contributions to psilocybin’s antidepressant effects: A mechanistic sub-analysis of a randomized controlled trial in treatment-resistant depression
PS03-3223. Beyond the psychotherapy debate: the participant support model as a safety-centred framework within clinical trials of psychedelics
PS03-3224. How does inflammation shape cancer-related transcriptional signatures in individuals with depression?
PS03-3225. Shared genetic architecture of anhedonia and insulin resistance–related traits
PS03-3226. Integrating birth weight and its polygenic architecture to shape longitudinal metabolic outcomes in first-episode psychosis
PS03-3227. Real-world effectiveness of antipsychotic medications for relapse prevention in first-episode psychosis with substance use disorder
PS03-3228. Variance decomposition of PANSS screening-to-baseline change reveals dominant subject-level variability and systematic rater effects in schizophrenia trials
PS03-3229. Psychosis-related disorganisation impairs the construction and verbal expression of relational cognitive maps from visual experience
PS03-3230. Integrated proteomic and metabolomic profiling reveals immuno-metabolic signatures in antipsychotic-naïve first-episode psychosis
PS03-3231. Biomarkers of immuno-metabolic dysfunction as risk factors and predictors of psychotic-like experiences: Analysis of the UK Biobank dataset
PS03-3232. Accelerated aging in schizophrenia: a systematic review and meta-analysis of multi-organ aging clocks
PS03-3233. Association between psychotic decompensation and serum urea, creatinine, and uric acid levels in patients with chronic kidney disease
PS03-3234. Automated speech analysis in psychosis: identifying linguistic and acoustic features across the psychosis spectrum
PS03-3235. Menopausal hormone therapy and the risk of new onset psychotic disorders: a Swedish register-based study
PS03-3236. Immunological differences between first-episode psychosis with and without circulating auto-antibodies: preliminary findings from the PHLAMES study
PS03-3237. When diagnostic stability misleads: emerging cognitive decline after late-onset psychosis
PS03-3238. Reward processing and delusions in schizophrenia: preliminary fMRI findings within the aberrant salience model
PS03-3239. Retinal-brain structural associations: inner macular GCIPL thickness relates to frontal gray matter volume
PS03-3240. Morphometric signatures of schizotypal traits and clinical psychosis: the role of early life adversity
PS03-3241. The correlation between auditory mismatch negativity and symptoms in patients with schizophrenia: a systematic review and meta-analysis
PS03-3242. Towards clinically relevant therapeutic targets: associations of metacognitive mastery and theory of mind performance with negative symptoms in schizophrenia
PS03-3243. Comparative effects of yoga and aerobic exercise combined with transcranial direct current stimulation on cognition in psychosis
PS03-3244. Developing a core outcome set for negative symptoms of schizophrenia: the SNAP project protocol
PS03-3245. Mass spectrometry imaging-based spatial lipid profiling of the human dorsolateral prefrontal cortex in health and schizophrenia
PS03-3246. Effectiveness of Risperidone ISM in acutely exacerbated schizophrenia in different countries: real world evidence from the RESHAPE study
PS03-3247. Clinical and health economic outcomes of an outcomes-based agreement to prevent relapse in schizophrenia
PS03-3248. Functioning and patient-reported medication satisfaction with risperidone-ISM by country in acutely exacerbated schizophrenia: real-world evidence from the RESHAPE study
PS03-3249. Data-driven biological subtypes in schizophrenia spectrum disorders and bipolar disorder: a systematic review
PS03-3250. Incidental detection of renal cell carcinoma during routine screening in a patient with schizophrenia: a case report
PS03-3251. Sedation is not sleep: treatment-resistant insomnia in a psychotic disorder responding to targeted GABAergic intervention
PS03-3252. Gender-specific associations between sleep quality, chronotype, and sexual function in psychiatric outpatients
PS03-3253. The efficacy of mirtazapine on sleep is independent of dose: a systematic review and meta-analysis
PS03-3254. Light therapy in primary and secondary sexual disfunctions
PS03-3255. Ventral pallidum activity links aggression experience to social-rank change
PS03-3256. The extended amygdala as a hub for social valence: anatomical connectivity and stress-induced alterations in mice
PS03-3257. Epigenomic embedding of childhood adversity links to disease risk and chronic immune changes
PS03-3258. Psychosocial and behavioural risk factors of cardiovascular disease: a cross-sectional study
PS03-3259. Pioglitazone alleviates post-weaning social isolation-induced cognitive impairments via PPAR-γ-Dependent BDNF upregulation in the prefrontal cortex and hippocampus of rats
PS03-3260. Administration of 50%-nitrous oxide during memory encoding increases intrusive memory detachment and impairs voluntary recall in healthy volunteers
PS03-3261. Antisense oligonucleotide–mediated modulation of SLC6A15 in neurons
PS03-3262. Changes in symptom networks of post-traumatic stress following a cognitive task intervention in trauma-exposed healthcare workers: a network intervention analysis
PS03-3263. Suicide in adolescence and related psychological variables and executive functions: a comparison with healthy controls
PS03-3264. Smartphone addiction and attention-deficit/hyperactivity disorder symptoms: a cross-sectional study of impulsivity as a key predictor
PS03-3265. Executive functioning in adolescents with attention-deficit/hyperactivity disorder and borderline personality traits: a comparative study
PS03-3266. Effects of liraglutide and insulin on hippocampal-dependent memory and neurodegeneration in diabetes-related cognitive decline in rats
PS04-4001. Effects of daily exogenous pregnenolone on downstream neuroactive steroids and their effects on drinking in individuals with alcohol use disorder
PS04-4003. Comparison of episodic future thinking and scene construction abilities in patients with alcohol use disorder and healthy controls
PS04-4004. Differences in online activities and problematic internet use among adolescents and young adults in a general sample of internet users
PS04-4005. Glp-1–associated suppression of cocaine craving following tirzepatide in undiagnosed adult ADHD
PS04-4006. Brain functioning during working memory task performance in young and long- term cannabis users
PS04-4007. Neural correlates of reinforcement learning models in substance use disorder: a systematic review
PS04-4008. Informing and preventing: a review of novel psychoactive substances in adolescents
PS04-4009. Catatonic syndrome with oneiroid disturbance of consciousness following polysubstance use: a retrospective case series
PS04-4010. Quantifying the extent to which different levels of cannabis use can discriminate clinical thresholds of paranoia
PS04-4011. Compulsive craving correlates with insomnia severity controlling for age, gender and depression among alcohol use disorder patients in early recovery
PS04-4012. Sex-specific role of neuroplasticity factor BDNF in behavioral, neurobiological, and metabolic effects of ketogenic diet in mice
PS04-4013. The psychiatric risk factor FKBP51 shapes stress resilience in astrocytes in a sex-specific manner
PS04-4014. Rewiring reward circuits in binge-eating disorder with combined MDMA and semaglutide therapy
PS04-4015. Optimising the maternal separation paradigm for early-life stress research: from behaviour to lipidomics
PS04-4016. Prenatal microglial depletion alters neurodevelopmental trajectories following early immune activation in mice
PS04-4017. Early IL-17A blockade prevents autism-like behavioural and molecular abnormalities in a maternal immune activation mouse model
PS04-4018. Disruption of Reelin signaling in a dual-hit mouse model of schizophrenia: impact of postnatal Δ9-tetrahydrocannabinol exposure in a poly(I:C) model
PS04-4019. From mother to adult: timing-dependent effects of Lactiplantibacillus plantarum on gut, brain and behaviour in mice
PS04-4020. NMDA antagonist models for antipsychotic testing in rats: a systematic review and meta-analysis
PS04-4021. Early JNJ-46356479 mGluR2 positive allosteric modulation attenuated adolescent apoptotic alterations in a postnatal ketamine-induced mouse model of schizophrenia
PS04-4023. The role of vitamin D in anxiety-like behavior and stress-response signaling (Tlr4/Nr3c1/Tgfb1) in rats
PS04-4024. Mental health burden among criminal defendants in a rural Greek court setting
PS04-4025. Real-world benzodiazepine prescribing for anxiety disorders: A Retrospective study
PS04-4026. Transdiagnostic dimensions of psychopathology and cognitive performance in a general population sample
PS04-4027. Mapping the interoceptive-internalising landscape: a network analysis and person-centred clustering of multidimensional interoceptive awareness in psychopathology
PS04-4028. Towards personalised biofeedback: assessing individual differences in optimal respiratory frequency within a virtual reality paradigm
PS04-4029. Validation of GAD-7 for postpartum anxiety screening in Latvia: psychometric and diagnostic performance
PS04-4030. Phase 1 studies assessing safety, tolerability, pharmacokinetics and pharmacodynamics of SYT-510, a first-in-class selective endocannabinoid reuptake inhibitor in healthy volunteers
PS04-4031. No weight gain or loss during 10 weeks of treatment with lavender oil preparation Silexan in patients with anxiety disorders
PS04-4032. Pharmacological characterization of SYT-510, a first-in class selective endocannabinoid reuptake inhibitor and clinical candidate for stress- and anxiety-related disorders[
PS04-4033. Persistent genital arousal disorder/genito-pelvic dysesthesia with severe psychiatric comorbidity and treatment refractoriness: a case report
PS04-4034. The effect of pharmacological and psychotherapeutic interventions on risk and loss aversion in anxiety
PS04-4035. Individual differences in hedonic response as measured by sucrose intake: Relationship with sensitivity to anxiogenic drugs and RNA m6A methylation
PS04-4036. Linking locus coeruleus (LC) integrity and reward-associated pupil dilation to understand anhedonia in major depressive disorder (MDD)
PS04-4037. Idiographic symptom networks fail to predict future symptom states across four ecological momentary assessment datasets
PS04-4038. Uncovering clinical utility and model behaviour of large language models in attention deficit hyperactivity disorder diagnosis
PS04-4039. The Youth-GEMs project: genetic and environmental interactions underlying trajectories of youth mental health
PS04-4040. Tracing semantic trajectories in attention deficit hyperactivity disorder
PS04-4041. Characterizing heterogeneity in cognitive aging through longitudinal trajectory clustering and phenotypic profiling
PS04-4042. Relationship among artificial intelligence and attitudes, mindfulness, and empathy
PS04-4043. Transfer learning of shared structure for robust psychosis classification across cohorts
PS04-4044. Longitudinal multidomain maternal profiles and neonatal outcomes in perinatal mental health
PS04-4045. Investigating childhood trauma and interacting risk and resilience factors to predict depression, psychosis, and high-risk individuals
PS04-4046. Heterogeneity in late-life depression: limited replication of resting-state EEG markers in a Korean community cohort
PS04-4047. Transcriptomic signatures of lithium treatment in peripheral blood mononuclear cells from bipolar disorder patients
PS04-4048. A composite cytokine score linked to brain structure predicts subsequent physical and mental health diagnoses
PS04-4049. Feasibility of a portable hybrid platform for assessing neuroplasticity and cognition during esketamine treatment in therapy-resistant depression
PS04-4050. PBMC lipidomic profiling as diagnostic and prognostic biomarkers in treatment-resistant depression: a pilot esketamine study in women
PS04-4051. A conserved neurometabolic ratio architecture across regions, field-strength and species
PS04-4052. NiSpace: neuroimaging spatial colocalization environment
PS04-4053. N-acetyl aspartate as a cognitive biomarker across the psychosis continuum
PS04-4055. Biomarker-guided stratification in psychiatry randomized trials: a transdiagnostic systematic review
PS04-4056. α9 Nicotinic acetylcholine receptor autoantibodies characterization in schizophrenic and bipolar disorder patients
PS04-4057. Modeling CDH13-dependent network dysfunction in human cortical cultures: From gene variants to circuit phenotypes
PS04-4058. Studying stress in BV2 microglial cells: from model development to translational perspectives
PS04-4059. The pedal platform: digital support for psychosocial treatment interventions
PS04-4060. High engagement and differential completion of emotion-focused exercises in a digital wellbeing application for bipolar disorder patients: real-world observational study
PS04-4061. A brief digital symbol-coding task outperforms clinical benchmarks for alzheimer’s trial pre-enrichment
PS04-4062. Who shares and why? Assessing psychiatric patients’ attitudes toward health data sharing using the standard health consent in Germany
PS04-4063. Recovery without reset: physiological-neural dissociation in anorexia nervosa – pilot study of orexin, endocannabinoid and opioid systems
PS04-4064. Metabolomic signatures of inflammation and energy metabolism across the body mass index spectrum in adolescence: from anorexia nervosa to obesity
PS04-4065. Longitudinal investigation of the microbiome-gut-brain axis in adolescent anorexia nervosa (MiGBAN 2.0)
PS04-4066. Transcranial direct current stimulation in anorexia nervosa: a double-blind pilot trial assessing autistic traits, emotion regulation, and somatic outcomes
PS04-4067. Neuropsychological and clinical outcomes of transcranial direct current stimulation in patients with anorexia nervosa: a randomized double-blind sham-controlled trial
PS04-4068. Psychiatric and systemic comorbidity burden in hidradenitis suppurativa: a nationwide Danish comparison with psoriasis and the general population
PS04-4069. Does comorbid borderline personality disorder worsen healthcare utilization and hospitalization outcomes in bipolar disorder? A nationwide retrospective study
PS04-4070. Linking tryptophan metabolites to cognitive dysfunction in chronic kidney disease
PS04-4072. Antipsychotic polypharmacy across psychiatric disorders: a nationwide cohort study
PS04-4073. Physicians’ awareness and referral practices regarding speech and language therapists in dysphagia management: a cross-sectional study
PS04-4074. Effects of combined oral contraceptive use on tryptophan metabolism and implications for serotonergic neurotransmission, memory and mood in healthy women
PS04-4075. Preliminary findings: The impact of executive dysfunction on anxiety severity in patients with attention-deficit/hyperactivity disorder across gender
PS04-4076. Gender dysphoria in monozygotic twins: a case report of two transgender male siblings receiving simultaneous cross-sex hormone therapy
PS04-4077. The M-Factor: Cross-disorder analysis of shared gut microbial features across psychiatric and non-psychiatric conditions
PS04-4078. Early-life tryptophan exposure drives long-term behavioral and gut–brain changes in a neurodevelopmental model
PS04-4079. Longitudinal associations between early-life gut microbiome development and socioemotional behavior
PS04-4080. Linking obesity to brain health through the gut–brain axis
PS04-4081. Circadian genetic vulnerability shapes trauma-related inflammation and white matter integrity in bipolar disorder
PS04-4082. Anti-Yo–associated autoimmune encephalitis presenting with catatonia: a case report
PS04-4083. Post-infectious anti-NMDA receptor encephalitis associated with HSV: a treatment-resistant case
PS04-4084. Adaptive immune dysregulation in schizophrenia: preliminary insights from a systematic review and pilot meta-analysis of lymphocyte subsets
PS04-4085. Regulatory T-cell transcriptomic signatures shared across psychosis and cardiometabolic outcomes
PS04-4086. Spectral power and functional connectivity alterations in obsessive-compulsive disorder based on resting-state EEG
PS04-4087. Efficacy of continuous Theta Burst Stimulation as an augmentation strategy in a sample of patients with Treatment-Resistant Obsessive-Compulsive Disorder
PS04-4088. Anterior capsulotomy for treatment-refractory obsessive-compulsive disorder: a systematic review of clinical outcomes in 407 patients
PS04-4089. Wheel running increases impulsivity through midbrain dopamine signaling in mice
PS04-4090. The impact of depression and anxiety on survival and treatment uptake in pancreatic cancer: a systematic review and meta-analysis
PS04-4091. Sleep, resilience, and coping in relation to depression and anxiety symptoms in children with Hashimoto’s thyroiditis: a pilot case-control study
PS04-4092. Increased mitochondrial DNA copy number in bipolar disorder but not in unaffected siblings
PS04-4093. Leveraging large multi-cohort datasets to investigate the replicability of neuroimaging findings in depression
PS04-4094. Retinal electrophysiology as a translational biomarker in mood disorders: a systematic review and meta-analysis
PS04-4095. Mineralocorticoid receptor activation and depression severity in early antidepressant treatment: longitudinal insights from the EMC study cohort
PS04-4096. Mapping dimensional symptom trajectories in bipolar disorder via digital phenotyping to enable targeted early interventions
PS04-4097. Prolonged and dysregulated loneliness states in chronic depression: evidence from an ecological momentary assessment study
PS04-4098. Real-world evidence on add-on esketamine or atypical antipsychotics for treatment-resistant depression: effects on suicide attempts, hospitalization, and mortality rates outcomes
PS04-4099. Mapping the evidence on the Patient Health Questionnaire-9 (PHQ-9): a living systematic review of studies on measurement properties
PS04-4100. Predictors of readmission and emergency-department reattendance after hospitalisation for suicidal ideation or attempt: a six-year cohort study
PS04-4101. Abstract patterns of mental disorders and suicidal behavior, and concordance in monozygotic adult twins: a decade-long prospective study
PS04-4102. Atypical symptoms associated with metabolic, but not inflammatory, biomarkers in bariatric surgery patients with depression
PS04-4103. Psychodermatological management of prurigo nodularis in an elderly patient: a case report
PS04-4104. Genetic evidence for repurposing immunomodulatory drugs for major depressive disorder
PS04-4105. Clinical and neurocognitive outcomes of subthreshold bipolar phenotype in pediatric attention-deficit/hyperactivity disorder: a 3-year preliminary follow-up
PS04-4106. Exploring the impact of quality of life on brain structure and resting-state connectivity in depression
PS04-4107. Illness characteristics and functional connectivity alterations across large-scale brain networks in bipolar disorder: the BipOld Study
PS04-4108. Peripheral gene expression and white matter microstructure in bipolar disorder: evidence for lithium-related effects
PS04-4109. Sex-specific associations between HSV-1/2 exposure, white matter microstructure, and depressive symptoms in mood disorders
PS04-4110. Metabolism meets mind: intranasal insulin modulates facial emotion recognition
PS04-4111. Sex-specific metabolic signatures and brain structural integrity in bipolar disorder: potential roles for leptin and ghrelin
PS04-4112. Peripheral lipid metabolism influences synaptic signalling to regulate cortical excitability and network plasticity associated with mental disorder phenotypes
PS04-4113. Mapping directional interactions in executive control networks during emotional and non-emotional conflict processing
PS04-4114. Brain metabolites and their association with maternal–neonatal attachment and parenting stress in postpartum depression: a magnetic resonance spectroscopy pilot study
PS04-4115. Filling the longitudinal gap: connectivity of the default mode and salience networks in severe depression across three time points
PS04-4116. Neural activity changes following cognitive behavioural therapy in major depressive disorder: a preregistered functional magnetic resonance imaging meta-analysis
PS04-4117. Secondary affective disorder associated with cerebral cavernomatosis: a case report
PS04-4118. High-density EEG during electroconvulsive therapy-induced seizures and other brain states: scalp potentials are global and highly multipolar
PS04-4119. Learning and relearning deficits in a mouse model of depression
PS04-4120. Transcranial direct current stimulation (tDCS) as maintenance therapy following rTMS in depression: a proof-of-concept study
PS04-4121. Transcranial direct current stimulation (tDCS) in perinatal depression: a naturalistic study of clinical outcomes and tolerability
PS04-4122. Sleep-related traits and lithium response in bipolar disorder: an approach using polygenic scores in the ConLiGen sample
PS04-4123. Real-world esketamine nasal spray treatment duration and dosing in patients with treatment resistant depression: findings from ECHO, a non-interventional study
PS04-4124. Real-world effectiveness of intranasal esketamine in treatment-resistant depression in a clinically complex population
PS04-4125. Effectiveness of esketamine/ketamine and non-invasive neuromodulation techniques on severity and cognitive-emotional regulation in treatment-resistant depression: systematic review and meta-analysis
PS04-4126. Antidepressant-associated acute manic switching in an adolescent with white matter abnormalities: neuropsychopharmacological and neurodevelopmental implications – case report
PS04-4127. Clinical correlates of non-responders to ketamine in terms of self-assessed life engagement among treatment-resistant depression patients
PS04-4128. When dissociation shapes experience: the impact of altered states on post-esketamine well-being
PS04-4129. Ketamine effects on life engagement in treatment-resistant unipolar and bipolar depression: post hoc analysis of Inventory of Depressive Symptomatology Self-Report
PS04-4130. Esketamine for treatment-resistant depression: comparing two maintenance protocols in an observational real-world study
PS04-4131. Clinical predictors of response to intranasal esketamine in treatment-resistant depression: a single-center real-world analysis from the Polish B.147 drug program
PS04-4132. Fully automated computerised cognitive assessments suitable for deployment in psychiatric disorders
PS04-4133. Clinical predictors of bipolar disorder onset in high-risk offspring: a systematic review
PS04-4134. Extended psychometric evaluation of the Turkish form of the Beck Hopelessness Scale—short version in adolescents and young adults
PS04-4135. Early life stress shapes the impact of inflammatory polygenic risk on depression and suicidality
PS04-4136. Anhedonia, but not depressed mood, shows genetic overlap with inflammatory and metabolic disorders
PS04-4137. Double-blind and open-label-extension results from a phase-3 trial of adjunctive seltorexant in adults with major depressive disorder with insomnia symptoms
PS04-4138. Behavioral alterations occur without changes in amyloid tracer distribution in a streptozotocin-induced mouse model of type 1 diabetes
PS04-4140. First episode of psychotic depression with catatonic features as an initial presentation of possible frontotemporal dementia – a case report
PS04-4141. Long-term risk of dementia, stroke and epilepsy after electroconvulsive therapy: a systematic review and meta-analysis of cohort studies
PS04-4142. Synthesis and molecular docking studies of novel thiazole derivatives as multi-target inhibitors against Alzheimer’s Disease
PS04-4143. Vascular endothelial dysfunction in vascular dementia: a mechanism-based approach with semaglutide
PS04-4144. Reduplicative paramnesia as an early neuropsychiatric manifestation of posterior cortical atrophy
PS04-4145. New disease-modifying treatments for Alzheimer’s disease: do they represent a paradigm shift with unforeseen chokepoints and millions of untreated patients?
PS04-4146. LPS-induced neuroinflammation models: neurodegenerative processes
PS04-4147. Impact of ADHD symptoms on quality of life: the mediating role of emotional dysregulation and substance use in university students
PS04-4148. A machine learning framework for autism risk gene discovery using large-scale mouse phenotyping data
PS04-4149. Rethinking inflammation in attention-deficit/hyperactivity disorder: decreased neutrophil gelatinase-associated lipocalin and tumor necrosis factor-alpha levels in a pediatric sample
PS04-4150. Linking early regulatory problems, cortical development and late-adolescent mental health
PS04-4151. Altered extracellular vesicle microRNAs in LGALS3BP mutant cerebral organoids: implications for cortical development
PS04-4152. Altered body ownership and multisensory integration in children and adolescents with attention-deficit/hyperactivity disorder
PS04-4153. Connection of dimensional ADHD-related traits, personal strengths and well-being in Hungarian youth
PS04-4155. Symptoms of attention-deficit/hyperactivity disorder among child and adolescent psychiatric outpatients in Zanzibar
PS04-4156. Cannabidiol for behavioural symptoms in paediatric autism spectrum disorder: a systematic review
PS04-4157. Cognitive performance in adults with ADHD assessed through virtual reality: Differences across ADHD presentations
PS04-4158. A 12-month remote monitoring study of patterns and predictors of medication adherence in adults with attention-deficit hyperactivity disorder (ADHD)
PS04-4159. Optimising antipsychotic use for behaviours that challenge in people with intellectual disability and the role of deprescribing
PS04-4160. Neuropsychiatric spectrum disorders associated with TANC2 mutations: a familial case series
PS04-4161. Altered reward processing and amotivational syndrome in young adult cannabis users: an fMRI study using a reinforcement learning task
PS04-4162. Abemaciclib partially restores blood–brain barrier integrity and P-gp function in a murine model of chronic stress
PS04-4163. Making blood oxygenation level dependent imaging interpretable: predicting regional cerebral metabolic rate of oxygen and blood flow via deep learning
PS04-4164. Intranasal esketamine expands key frontal and hippocampal regions and reduces serum neurofilament levels in patients with major depressive disorder
PS04-4165. From suppression to awareness: temporoparietal junction dynamics support attentional reorientation during memory control
PS04-4166. Early problems with crying, sleeping and feeding are associated with altered connectivity of the allostatic interoceptive system later in life
PS04-4167. Methodological sources of neuroimaging outcomes in acute cortisol challenge studies
PS04-4168. Heartfulness meditation effects on affective symptoms and neural function in healthy adults
PS04-4169. Intranasal oxytocin transiently normalises amygdala-centered functional connectivity during facial emotion recognition in psychosis
PS04-4170. Structural and functional neural correlates of developmental and psychosocial risk factors for lifetime suicidal ideation: a transdiagnostic neuroimaging study
PS04-4171. Transcriptional profiling of monocytes in early-onset obsessive-compulsive disorder, Tourette syndrome and autism spectrum disorder
PS04-4173. Psychogenic non-epileptic seizures at a national epilepsy centre: a case series integrating psychiatric, traumatic and neurophysiological profiles
PS04-4174. Effects of (±)-9α-Hydroxyhexahydrocannabinol on excitability of hippocampal neurons
PS04-4175. Altered perturbational cortical complexity across cognitive biotypes in psychosis and bipolar disorder: a transcranial magnetic stimulation electroencephalography study
PS04-4176. Electrophysiological comparison of source monitoring performance: the significance of recollection and familiarity across virtual reality and screen-based environments
PS04-4177. PASTA – from grams to symptoms: visuo-motor deficits as transdiagnostic mediators between preterm birth and adolescent mental health
PS04-4178. Associations of alexithymia and personality traits with symptom severity in patients with depressive and anxiety disorders
PS04-4179. Efficacy of multimodal interventions for adult attention-deficit hyperactivity disorder: research plan for a systematic review and network meta-analysis
PS04-4180. Social processes in dyadic interaction: a systematic review of second-person neuroscience
PS04-4181. Birth weight, cognitive reserve and cognitive performance in schizophrenia
PS04-4182. From inhibition to context sensitivity: distinct executive function contributions to social cognition
PS04-4183. Empathy, self-compassion, burnout, and alexithymia in first- and fifth-year medical students: a cross-sectional study
PS04-4184. The effect of slMFB DBS in depression and OCD on reaction time in a monetary incentive delay task
PS04-4185. Clinical effects of transcranial magnetic stimulation in comorbid conversion disorder and major depressive disorder: a case report
PS04-4186. Efficacy of transcranial electrical therapy (tES) in adult attention deficit disorder: a systematic review
PS04-4187. Network initiative: advancing patient-centered and regulatory-ready clinical outcome strategies in early-phase neuropsychiatric drug development
PS04-4188. Comparative efficacy and safety of non-invasive brain stimulation therapy for schizophrenia: a systematic review and network meta-analysis
PS04-4189. Physiological and hematological predictors of early postpartum depressive symptoms in women after childbirth
PS04-4190. FKBP5 rs3800373 genotype is associated with antipsychotic treatment response in a Greek schizophrenia-spectrum cohort
PS04-4191. Escitalopram dose escalation, hyponatremia, and acute confusional state: a case report and literature review
PS04-4192. Beyond pharmacological staging: biopsychosocial complexity in esketamine-referred treatment-resistant depression
PS04-4193. Anhedonia mediates short-term anti-suicidal effects of intranasal esketamine in major depressive disorder
PS04-4194. The Oxytocin Brain Imaging Data Exchange (OBIDE) Initiative
PS04-4195. DT-101, an α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) positive allosteric modulator (PAM): Phase 1 safety, pharmacokinetic, and pharmacodynamic data in healthy volunteers
PS04-4196. Effects of 4 weeks of serotonergic treatment on emotional processing in individuals with low vs high neuroticism: a neuroimaging study
PS04-4197. Functional outcomes and clinical response to long-acting injectable ISM risperidone: a retrospective study
PS04-4198. Go green or go blue: a protocol proposal for sulforaphane as a therapeutic intervention for young adult major depressive disorder
PS04-4199. Effects of repeated low-dose LSD on neuropsychological functioning in adults with ADHD: A randomized placebo-controlled study
PS04-4200. Evenamide in patients with poor response to antipsychotics or treatment-resistance: unique benefits extending to social functioning and life engagement domains
PS04-4201. ML-007C-MA, a novel investigational M1/M4 muscarinic agonist in Phase 2 development for the treatment of schizophrenia and Alzheimer’s disease psychosis
PS04-4202. Clinical decision support systems in psychiatric drug treatment: a systematic review on current use and treatment impact
PS04-4203. Immunological correlates of antidepressant response to serial oral ketamine in major depressive disorder and bipolar depression
PS04-4204. Hemolytic anemia as a rare adverse event of donepezil: relevance of hematological monitoring in the treatment of dementia
PS04-4205. Age-dependent effects of cannabis use on functional brain connectivity: evidence from a longitudinal resting-state fMRI study
PS04-4206. Acute effects of the synthetic cannabinoid JWH-018 in humans: subjective experience, cognition, and brain activity
PS04-4208. Synaptic plasticity mechanisms of psychoplastogens in major depressive disorder: a systematic review of clinical studies
PS04-4210. Efficacy and safety of glucagon-like peptide-1 receptor agonists in patients with schizophrenia spectrum disorders treated with antipsychotics: a meta-analysis
PS04-4211. Towards precision medicine in ADHD: longitudinal assessment of visuospatial working memory precision during methylphenidate titration
PS04-4212. Schizophrenia-derived extracellular vesicles drive microglial alterations: neurodevelopmental implications and potential for targeted drug delivery
PS04-4213. From projection to precision: stress and distress variables in the Rorschach Performance Assessment System—a systematic review and meta-analysis
PS04-4214. Associations between movement and acceptance of an effortful cognitive task in participants with low mood
PS04-4215. External validation and recalibration of the psychosis metabolic risk calculator in young adults with chronic psychotic disorders in the Netherlands
PS04-4216. Impact of group psychoeducation on insight, treatment adherence, quality of life and the feeling of loneliness in patients with schizophrenia
PS04-4217. Gut microbiome depletion alters psilocybin-induced prosocial effects in adult mice
PS04-4218. Durability of efficacy and safety of COMP360 for treatment-resistant depression across 26 weeks: a double-blind, randomised, controlled phase 3 study
PS04-4219. Efficacy and safety of COMP360 psilocybin for treatment-resistant depression in two phase 3 double-blind randomised controlled studies
PS04-4220. Serotonin system stimulation and empathy: a comparative investigation of psilocybin, MDMA, and methylphenidate
PS04-4221. From rigidity to flexibility: ketamine-induced changes in cognitive flexibility in major depressive disorder
PS04-4222. Multi-modal deep phenotyping reveals biologically coherent subgroups in treatment-resistant schizophrenia
PS04-4223. Evolutionarily young brain-regulatory variants disproportionately carry schizophrenia heritability across European and East Asian ancestries
PS04-4224. Opioids and psychosis: a narrative review of a paradoxical relationship
PS04-4225. Are midlle-aged adults more prone to mental illness after longlasting conversation with an AI chatbot?
PS04-4226. Peripheral inflammatory indices versus clinical and cognitive predictors of one-year functional outcome in first-episode psychosis
PS04-4227. Auditory and visual distortions in schizophrenia: associations with positive symptoms and hallucination proneness across modalities
PS04-4228. Nonspecific inflammatory markers in first-episode psychosis: Clinical relevance and functional correlates
PS04-4229. Negative symptoms in psychotic outpatients: insights from the Geneva Psychosis Cohort
PS04-4230. Cytokines in first-episode psychosis
PS04-4231. Exploring neuroanatomical patterns of primary progressive aphasia in patients with primary psychiatric disorders
PS04-4232. Data-driven symptom phenotypes in psychosis: derivation and neuroimaging validation through machine learning
PS04-4233. Neurobiological signatures of stressor reactivity in early psychotic and affective disorders
PS04-4234. Influence of current voice-hearing on modality-specific intentional inhibitory control
PS04-4235. Double bookkeeping in schizophrenia: a literature review
PS04-4236. Do cultural factors and language influence efficacy outcomes? Results from Study 008A in Latin America and Asia
PS04-4237. Beyond the acute episode: D2 receptor pharmacology and risk-stratified antipsychotic decisions in acute and transient psychotic disorder
PS04-4238. Real-world impact of risperidone ISM on healthcare utilization: a multicentre retrospective study
PS04-4239. Healthcare professional preferences for long-acting injectable treatments in schizophrenia: a discrete choice experiment
PS04-4240. The effects of adjunctive N-Acetylcysteine and cognitive training on working memory performance in adolescents with recent-onset psychosis: randomized double-blind-controlled clinical trial
PS04-4241. Brain age in antipsychotic-naive first episode of psychosis, a longitudinal study
PS04-4242. Switching to the novel 2-month Aripiprazole 960 mg in real-world: universal efficacy across other LAIs and oral transitions
PS04-4243. Risperidone in situ microparticles in psychiatric emergency settings: pharmacokinetic rationale, clinical evidence and practical implications
PS04-4244. Asymptomatic pulmonary embolism in psychiatric patients
PS04-4245. Real-world profiling of adolescents for precision psychiatry: gender-specific phenotypes in treatment-resistant early-onset schizophrenia
PS04-4247. Sleep-disordered breathing and sleep fragmentation in relation to atrial fibrillation risk: a systematic review and meta-analysis
PS04-4248. Efficacy of pitolisant in treatment resistant narcolepsy with cataplexy: a clinical case report
PS04-4249. The current evidence for the efficacy and tolerability of modafinil and armodafinil in treating narcolepsy
PS04-4250. Real-world clinical outcomes of daridorexant in chronic insomnia disorder refractory to previous pharmacological treatment
PS04-4251. Mapping the neural architecture of self-compassion: a multimodal resting-state study
PS04-4252. Signalling of the corticotropin-releasing factor system in the nucleus accumbens impacts maternal aggression in lactating rats
PS04-4253. Endothelial glycocalyx degradation links post-traumatic stress disorder to cardiovascular dysfunction
PS04-4254. Detailed item memory at the cost of spatial context: an fMRI mechanism for intrusive memories after trauma-analog exposure
PS04-4255. The role of lived experience background in coping and compassion fatigue among mental health professionals
PS04-4256. Trauma-focused psychological therapies for chronic pain in trauma-exposed adults: a systematic review and meta-analysis
PS04-4257. Dissociation in trauma-related psychopathology: a transdiagnostic clinical perspective
PS04-4258. Treatment-resistant suicidality in a trauma-related disorder initially diagnosed as schizophrenia: a transdiagnostic perspective and response to electroconvulsive therapy
PS04-4259. From childhood trauma to dissociation: the role of interoceptive dysregulation in altered self-experience
PS04-4260. Negative impact of antidepressant drugs on sleep: a narrative review
PS04-4261. From benzodiazepines to off-label sedatives: Shifting sleep-promoting drug use in schizophrenia spectrum disorders across Nordic registries and a clinical cohort
PS04-4262. Long-acting injectable aripiprazole in borderline personality disorder: targeting non-adherence and behavioural dysregulation
PS04-4263. Late-onset bipolar I disorder after resection of a right frontal falx meningioma: tumour, surgery, or medication?
PS04-4264. Distinct epitope-derived humoral immunotypes define the immune landscape of treatment-resistant schizophrenia
PS04-4265. Dimensional Personality profiles in Turkish-origin individuals and a comparison group in Germany: a multivariate analysis: cultural context and migration-related experiences
PS04-4266. A predictive modelling pipeline for deriving treatment response-sensitive personalised neural circuits for anxiety and depression
RS.01. Academic perspective
S01.02. The need for large multinational studies: from a large clinical cohort initiative to a european platform trial for depression
S02.01. The interplay between stress, circadian clocks, and energy metabolism
S02.02. Gut microbiota as a key regulator of stress responsivity via the circadian system
S02.03. Prebiotics: a tool to fight stress-induced sleep and diurnal rhythm disruptions?
S02.04. Circadian disruption: pathways to mental disorder
S03.01. Blocking memory reconsolidation with minocycline to modulate intrusive memories across diagnoses: first findings from the MEMOCYCLINE trial
S03.04. Impact of rare and common genetic risk variants for schizophrenia on microglia activation
S04.01. Sex Differences in bipolar disorder – lessons from patients and from a novel bipolar disorder-like mouse model
S04.02. Genomic discoveries in bipolar disorder inform biology and clinical outcomes: an update
S04.04. Risk and resilience for cognitive impairment in bipolar disorder: toward a personalised approach
S05.01. Effects of gut microbiota-derived metabolites on iPSC-derived dopaminergic neurons from individuals with ADHD
S05.02. Inflammation: a new target for trauma and chronic stress in ADHD
S05.03. The hidden switches: unlocking ADHD through epigenetics
S05.04. New insights on polygenic risk in ADHD
S06.01. Retinal neural and microvascular findings in psychotic disorders and high-risk states
S06.04. The retina as a window to investigate synaptic dysfunction in schizophrenia
S07.02. The blood-brain barrier as a target to restore brain function
S08.01. Characterising symptom trajectories using electronic health records and natural language processing
S08.02. Smartphone-based digital phenotyping to predict emerging affective episodes in bipolar patients: a 12-month ambulatory study
S08.03. Precision psychiatry through digital phenotyping - Lessons learned from three longitudinal studies in major depressive disorder
S08.04. Using digital phenotyping for the classification of bipolar disorder and unipolar disorder: findings from machine learning models
S09.01. Towards an integrated clinical and psychobiological model for borderline personality disorder
S09.02. Peripheral molecular markers of borderline personality disorder and modulation by psychotherapy
S09.03. Sleep fails where needed the most: REM sleep and impaired overnight adaptation to emotional distress in Borderline Personality Disorder: clinical implications
S09.04. Interaction of neuroimaging and treatment in borderline personality disorder
S10.01. Fear learning and extinction in anxiety disorders: from mechanisms to therapies
S10.02. Shared genetic background and bidirectional risks between anxiety disorders and general medical conditions
S10.03. Next-generation pharmacotherapies for anxiety: targeting fear, unease and worry
S10.04. Harnessing digital health for anxiety disorders: apps, artificial intelligence, and virtual reality
S11.02. Bridging the gap between obstetrics/gynecology and psychiatry with population-based cohorts to understand mental health risk factors
S12.01. Connectivity between personalized rTMS targets and stimulated normative functional brain networks as a marker of treatment response in OCD
S12.02. Assessing glymphatic function in major depressive disorder using DTI-ALPS and AQP4-related miRNAs
S12.03. Investigating the role of the human pgACC in cost-benefit decision-making using transcranial ultrasound stimulation
S12.04. From validation to innovation: TALLYHO/JngJ mouse model for T2D-related cognitive impairments and lipid-based therapeutic testing
S12.05. Studying anxiety in an animal model in eating disorders
S12.06. Ventral striatum control of spatial memory consolidation in the hippocampus
S13.03. Development of the gut microbiota throughout the first year of life and its association with socio-emotional development into childhood
S14.01. Dysregulation of extracellular matrix in psychiatric disorders: impact on the connectivity of inhibitory networks
S14.02. Transient dysregulation of extracellular matrix modulates extrasynaptic transmission and can reactivate neuroplasticity in brain diseases
S14.03. The fourth partner in synaptic functions: the development of treatment for memory enhancement through modulation of perineuronal nets
S14.04. Role of metalloproteinase inhibitors in human aversive memory
S15.01. Cannabidiol versus risperidone as monotherapy for cannabis-related psychosis: a randomised double-blind clinical trial (CANRISE)
S15.02. Altitude-like cognition training to promote neuroplasticity and cognitive functions
S15.06. PDE10A inhibition in schizophrenia: unique pharmacodynamic profile of CPL’36 improves positive and negative symptoms – phase II results
S15.07. Muscarinic agonism with ML-007C-MA for the treatment of schizophrenia: results from the phase 2 randomized, double-blind, placebo-controlled ZEPHYR trial
S16.01. Deep brain stimulation in animals: effect on motivation and its relevance for apathy in Parkinson's disease
S16.02. Trigeminal nerve stimulation in children/adolescents with ADHD
S16.03. Repetitive transcranial magnetic stimulation as adjuvant to exposure therapy in obsessive-compulsive disorder
S17.01. A novel method to disentangle tightly linked risk and resilience genes in psychiatric disorders
S17.02. Identifying environmental risk and resilience factors determining mental health states in endocrine-sensitive life stages
S17.03. Identification of clinical and psychological factors associated with resilience in patients with schizophrenia using machine learning
S17.04. Enhancing resilience and frontohippocampal connectivity in youth with psychotic experiences
S18.02. Novel mechanisms of alcohol use disorder revealed by multidimensional animal model
S18.03. Improving translational impacts for understanding the psychiatric risks of adolescent nicotine and cannabis use with edible and vaping administration models
S19.02. The role of psilocybin in the emergence of new brain cells and the treatment of depression-like symptoms
S20.02. From clinical records to conversations: generative artificial intelligence for symptom extraction and assessment
S20.03. Clinical neuroscience needs an algorithmic fairness perspective
S20.04. The geometry of thought: mapping psychiatric cognition from speech and multimodal artificial intelligence inference
S21.02. Persistent cognitive side effects after ECT: treatment resistant or not?
S21.03. Pharmacogenomics of treatment resistance: challenges, pitfalls and new perspectives
S22.01. Are anxiety and other stress-related disorders associated with increased mortality?
S22.02. Incidence of and mortality from respiratory disease in people with bipolar disorder
S22.03. Influence of physical health comorbidity and disparities on life expectancy in patients with schizophrenia
S22.04. Influence of life events on inflammation, synapses and suicidality
T.02. Resting state default mode network connectivity and social dysfunction in dopamine d2 autoreceptor knockout mice
T.03. Exploring depression through brain morphology and inflammation
T.04. Uncovering how maternal stress impacts the neuroimmune system in pregnancy: from brain to placenta
TP01.01. Highlights in adult autism
TP03.01. Highlights in women's mental health
TP05.01. Highlights in obsessive-compulsive and related disorders
TP06.01. Highlights in old age
ASCP Annual Meeting 2026 — Abstracts
No abstracts match your search.